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9General introduction
INTroDucTIoN
Thyroid hormone is important in virtually all metabolic processes in the 
human body. Deficiency of thyroid hormone (hypothyroidism) results 
in fatigue, weight gain, cold intolerance and constipation, and may 
eventually lead to depression, hypertension and atherosclerosis. The 
synthetic thyroid hormone levothyroxine (LT4) is the treatment of choice 
to reduce these symptoms. In clinical practice, however, adequate 
treatment is not always easy to achieve.
This thesis originally started with a clinical observation in a hypothyroid 
patient on LT4 treatment with persistent complaints. The research 
went from bedside to bench and focused on the uptake of the thyroid 
hormone T4 by the intestine. We studied the effect of switching from 
morning LT4 intake to bedtime LT4 intake on thyroid hormone levels and 
profiles. Subsequently, the quality of life (QOL) in treated hypothyroid 
patients was studied. Thyroid hormone transport in the enterocyte 
(small intestinal cell) was characterized in an intestinal cell model. The 
results of these basal experiments provided important information, 
offering more understanding of reduced absorption of LT4 in several 
clinical settings.
HyPoTHAlAmus-PITuITAry-THyroID AxIs
Thyroid hormone is produced by the thyroid gland, which is located 
in the neck. The production of thyroid hormone is regulated by the 
hypothalamus-pituitary-thyroid axis (Figure 1). Thyrotropin releasing 
hormone (TRH), produced by the hypothalamus, stimulates thyrotropin 
(thyroid stimulating hormone, TSH) secretion by the anterior pituitary. 
By stimulating the TSH receptor, TSH activates the thyroid gland to 
produce thyroid hormones. In the follicular cells of the thyroid gland 
the important element iodide is incorporated into thyroglobulin by 
thyroperoxidase (TPO), followed by the production of mono- and 
diiodothyrosines. TPO also catalyses the coupling of these iodothyrosines 
to form 3,3’,5-triiodothyronine (T3) and 3,5,3’,5’-tetraiodothyronine 
(thyroxine, T4). Finally, the iodothyronines are released into the 
circulation. In humans, the thyroid gland predominantly produces the 
inactive prohormone T4 and a small amount of the active hormone 
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triiodothyronine (T3). 80% of the circulating T3 is produced outside the 
thyroid by peripheral conversion of T4 by the iodothyronine deiodinases 
type 1 and 2 (D1 and D2). D1 is present in liver and kidney, and 
D2 is mainly present in brain, brown adipose tissue, skeletal muscle 
and heart. Because thyroid hormone gives negative feedback to the 
hypothalamus and pituitary gland, the production of TRH and TSH can 
be downregulated. This ascertains that serum thyroid hormone levels 
are maintained within a narrow range.
HyPoTHyroIDIsm
Hypothyroidism is the lack of thyroid hormone in the serum, resulting in 
a generalized slowing of metabolic processes in the body. The cause of 
the reduced thyroid hormone production can be located in the thyroid 
gland itself (primary hypothyroidism), in the pituitary gland (secondary 
hypothyroidism) or in the hypothalamus (tertiary hypothyroidism). In 
primary hypothyroidism T4 and T3 levels are low, causing the pituitary 
gland to produce high levels of TSH to stimulate the thyroid gland. 
In secondary and tertiary hypothyroidism the TSH production is low 
(or inappropriately normal) resulting in low serum thyroid hormone 
levels. This thesis will mainly focus on the treatment of primary 
hypothyroidism.
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Figure 1. The hypothalamus-pituitary thyroid axis
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There are several causes of inadequate production of thyroid hormone 
by the thyroid gland. Congenital hypothyroidism is a lack of thyroid 
hormone at birth, usually because the thyroid gland has not developed 
during fetal growth. Since the introduction of postnatal screening in 
the Netherlands this condition is diagnosed shortly after birth. Prompt 
initiation of LT4 treatment after diagnosis, prevents the development of 
cretinism (mental retardation and impaired growth) in these children.
Environmental iodine deficiency is the most common cause of 
hypothyroidism on a worldwide basis: iodide is an essential element 
in thyroid hormone production. In areas of iodide sufficiency, like the 
Netherlands, the most common cause of hypothyroidism is autoimmune 
thyroiditis (Hashimoto’s thyroiditis). It is characterized by circulating 
thyroid autoantibodies, which include anti-thyroid peroxidase antibodies 
(TPOAb), anti-thyroglobulin antibodies (TgAb) and TSH receptor 
antibodies (TSHRAb).
Hypothyroidism may also occur after radioiodine or surgical treament for 
hyperthyroidism, thyroid cancer or benign nodular thyroid disease and 
after external beam radiation for head-and-neck related malignancies. 
Finally, certain drugs such as lithium (1), amiodarone (2) and iodide 
excess (3) can induce hypothyroidism that requires treatment. Recently, 
tyrosine kinase inhibitors, most notably sunitinib, have been discovered 
to cause hypothyroidism as well (4).
TreATmeNT oF HyPoTHyroIDIsm
The treatment of hypothyroidism has only been possible since the end of 
the 19th century. After the anatomical identification of the thyroid gland 
in the neck in 1656, the function of the gland remained unresolved for 
another 200 years (5). It was considered a rudimentary structure, with 
no specific function in the adult human. In 1883 the Swiss physician 
Theodor Kocher presented a paper at the XII. Congresses der Deutschen 
Gesellschaft fur Chirurgie zu Berlin describing his patients after thyroid 
surgery because of mechanical problems caused by struma (6). After 
a remarkable deterioration in the condition of one of his patients 
postoperatively, he called to follow up 101 patients he had performed 
thyroid surgery on. In those cases where he had performed a total 
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thyroidectomy he concluded that symptoms were similar to patients 
with cretinism. This observation resulted in the hypothesis that an 
abnormally low secretion of thyroid hormone from the thyroid gland 
(hypothyroidism), could lead to a decrease in basal metabolic rate and 
cause symptoms of fatigue, weight gain and cold intolerance.
In 1891 Murray (United Kingdom) first described treatment of a 
human patient with hypothyroidism with subcutaneously injected 
sheep thyroid extract, which helped to resolve most symptoms (7). 
Soon after, it was discovered that oral administration of thyroid extract 
was effective. Animal-derived dessicated thyroid gland (Thyranon in 
the Netherlands) was the treatment for hypothyroidism for the next 
decades. However, the content of thyroid hormone varied in dessicated 
thyroid hormone preparations, and contained supraphysiologic levels 
of T3. Purified thyroxine (T4) was discovered in 1914, and in 1930 
synthetic thyroxine was developed. By the 1960s, it was known that 
thyroxine was the essential hormone produced by the thyroid gland, and 
that most T3 was produced at tissue level by deiodination of thyroxine. 
In the Netherlands, synthetic thyroxine, levothyroxine (LT4), became 
available in the 1970s when the pharmaceutical company Organon 
introduced Thyrax. After intake, LT4 has a half-life of 6 days, thus 
providing the body with stable and physiological quantities of T3 (8, 9). 
International guidelines therefore recommend LT4 monotherapy as the 
best substitution therapy in hypothyroidism (10). Over the years the 
prevalence of hypothyroidism has increased, with now 450 thousand 
people taking LT4 in the Netherlands (Source: GIP/Zorginstituut 
Nederland, update 07-03-2014).
ADequATe TreATmeNT oF HyPoTHyroIDIsm
Adequate replacement therapy of LT4 is defined by reaching normal free 
T4 (FT4) and thyrotropin (TSH) levels. As there is a negative feedback 
of T4 and T3 on TSH secretion by the pituitary gland, TSH is a good 
marker of peripheral thyroid hormone action. Therefore, TSH is the 
most reliable marker of adequate replacement treatment in the follow 
up of hypothyroid patients. To reach stable TSH and thyroid hormone 
levels, an adequate uptake of LT4 by the small intestine is essential. As 
absorption is decreased by several drugs and simultaneous food intake 
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(11, 12), Dutch prescribing information states that LT4 should be taken 
30 minutes before breakfast. American prescribing information advises 
an interval of 60 minutes before taking any food. In addition, interfering 
drugs should be taken 2-6 hours after LT4 ingestion (11). For patients 
these instructions can be inconvenient because of their (work)schedule, 
concurrent illnesses (eg diabetes) and other drugs that should be taken 
before or with meals.
We observed several patients whose thyroid hormone levels and 
symptoms improved when LT4 was taken at bedtime instead of in the 
morning (following the patient information leaflet). One illustrative case 
is described in the frame on this page. These observations made us 
wonder if LT4 at bedtime was as good, or even better, than LT4 ingestion 
in the morning. A review of the literature showed that it had never been 
studied systematically whether intestinal LT4 absorption is better when 
the stomach is empty in the morning than at night.
clINIcAl cAse
A 45 year old hypothyroid male patient, who happened to be a 
pharmacist, was referred to our outpatient clinic for complaints 
of fatigue. Since diagnosis, several years before, he had been 
treated with LT4, in a dosis of 150 μg daily (1.8 μg/kg) The 
laboratory values indicated inadequate substitution of the 
hypothyroidism (TSH 11.8 mU/l (normal 0.4- 4.0 mU/l) and FT4 
18.4 pmol/l (normal 10-24 pmol/l). As he reported to take the 
thyroid hormone tablet first thing in the morning, we suggested 
to take the tablet at bedtime. At the return visit after 6 weeks, he 
reported a significant improvement in well being. Interestingly, 
his TSH level was also normalized (TSH 3.5 mU/l, FT4 21.0 
pmol/l).
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THyroxINe INTAke AT BeDTIme
Because of the clinical observation described above, we decided to 
study the effect of bedtime intake of LT4 on thyroid hormone levels and 
quality of life (QOL). The optimal study design to investigate morning 
versus bedtime LT4 intake was considered to be a randomized double 
blind trial. However, the best time for blood collection in such a trial 
could not easily be determined. Some reports have mentioned acute 
changes in FT4 levels following ingestion of LT4 (13). Furthermore, TSH 
has a circadian rhythm (14), which might be influenced by altering the 
administration time of LT4. Before initiating the randomized trial, we 
decided, therefore, to study the effect of bedtime LT4 intake on TSH and 
thyroid hormone levels and their circadian rhythm.
circadian rhythm thyroid hormones
Various hormones in the human endocrine system exhibit a circadian 
rhythm, facilitating anticipation of and adaptation to environmental 
fluctuations (15). Cortisol, for example, peaks during the morning and 
prepares the body for typical stresses associated with wakening. Thyrotropin 
(TSH), released by the pituitary gland, also exhibits a circadian rhythm. 
Serum TSH levels increase in the evening, reach a maximum in the early 
night and are followed by a progressive decrease during the night and low 
levels during the day (14, 16). TSH secretion is influenced by thyrotropin 
releasing hormone (TRH), negative feedback of thyroid hormones and 
various other factors (17). The circadian rhythm is still present in mild 
hypothyroidism, disappears in overt hypothyroidism, but is restored with 
LT4 substitution (18). There are conflicting data on a diurnal rhythm in T4 
and T3 levels (19, 20). Some studies show that T4 rises after LT4 ingestion. 
The influence of the time of LT4 ingestion on circadian patterns of thyroid 
hormones is unclear, and changing the administration time of LT4 to bedtime 
in patients with primary hypothyroidism might influence the nocturnal TSH 
surge and the circadian variation of serum TSH. In that case, taking one 
blood sample per day may not represent average hormone levels, as this 
single blood sample may be drawn on different moments of the hormone 
cycles. chapter 2 describes the 24 hour patterns of thyroid hormones with 
morning and bedtime LT4 intake in 11 patients (21). The aim of this study 
was to confirm the clinical observation of improvement of thyroid hormone 
levels when switching to bedtime LT4, and to determine the optimal time for 
blood sample collection in a future randomized trial.
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morning versus evening lT4 intake
As the pilot study in 11 patients showed significant differences in thyroid 
hormone levels, we wanted to confirm these findings in a randomized 
double blind cross over trial on morning versus bedtime LT4 ingestion. 
The pilot study had also shown that blood sampling could take place 
in the morning as usual. chapter 3 describes the trial including 90 
consecutive patients of our outpatient clinics treated for hypothyroidism. 
During the first 3 months patients took LT4 in the morning and placebo 
at night and switched to bedtime LT4 and morning placebo for another 
3 months (or vice versa). Thyroid hormone levels and vital parameters 
were checked every 6 weeks. We also studied the quality of life (QOL), 
often mentioned by hypothyroid patients to be diminished. Therefore, the 
patients completed 3 QOL questionnaires and a symptom score at 0, 3 
and 6 months. The cross over design enabled us to compare QOL between 
morning and bedtime LT4 intake, with patients being their own controls.
reDuceD qol IN HyPoTHyroIDIsm
Previous trials have shown that despite normalization of serum thyroid 
hormones by suppletion with LT4, many patients with treated primary 
hypothyroidism still complain of a reduced QOL (22, 23). The reason 
for this reduced QOL has not been completely elucidated. As symptoms 
of hypothyroidism improve after starting LT4 replacement therapy, it 
seems plausible to assume that there is a correlation between thyroid 
hormone parameters and QOL. Attempts to improve QOL by aiming at a 
lower serum TSH level (24, 25), by adding liothyronine (T3) substitution 
to thyroxine (26), or by making small changes in the LT4 dose (27), 
have not resulted in improvement in well-being. Of course the narrow 
individual setpoint for thyroid hormone levels makes it difficult to find 
the right substitution dose for individuals (28). Another aspect in the 
treatment of hypothyroidism is that serum levels may not represent 
thyroid hormone levels in different tissues (29). A marker for thyroid 
hormone tissue levels would be helpful to improve treatment.
More knowledge on the reason of reduced QOL in hypothyroid patients, 
would help to have a better understanding of patients’ complaints and 
to optimise their treatment. In chapter 4 we analyse the correlation 
between QOL and the various measured parameters in our randomized 
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trial. The correlation of thyroid hormone levels, vital parameters and 
autoimmune antibodies and QOL is described.
THyroID HormoNe uPTAke IN THe GuT
While we were conducting the clinical studies on LT4 administration, 
we gathered the available information on the factors influencing LT4 
uptake by the intestine. Apparently, the mechanism of thyroid hormone 
uptake in the small intestine had not been completely cleared up. We 
contacted the research laboratory of the department of Endocrinology 
at the Erasmus Medical Centre, which has great expertise in research on 
thyroid hormone transport (30), and decided to perform experiments to 
characterise thyroid hormone transport in intestinal cells.
Previous studies had shown that uptake of LT4 takes place in the 
duodenum, jejunum and ileum, and is approximately 70-80% (31). As 
thyroid hormones have to enter the cell to be metabolised by deiodinases 
and to activate the nuclear thyroid hormone receptor, transport of thyroid 
hormone over the cell membrane is required. Based on the lipophilic 
structure of thyroid hormones, it was previously assumed that thyroid 
hormones enter the cell through passive diffusion (31, 32). However, 
experimental evidence and clinical studies over the last decades have 
shown clearly that thyroid hormones traverse the cell membrane mainly 
through transporters (33, 34). Thyroid hormone uptake has different 
characteristics across cell types, with regard to ligand specificity, energy 
(ATP) dependence, Na+-dependence and interactions with a variety of 
compounds (33). It has become apparent that different transporters 
facilitate thyroid hormone uptake in different tissues. Over the last years 
several thyroid hormone transporting proteins have been identified. These 
include Na+/tauchlorate cotransporting polypeptide (35, 36), fatty acid 
translocase (37), multidrug resistance-associated proteins (38), amino 
acid transporters (39) and members of the organic anion-transporting 
polypeptide (OATP) family (40). It has, however, not been clarified up till 
now which transporter is responsible for thyroid hormone uptake by the 
intestinal cell. This made us look for a cell line to study the characteristics 
of thyroid hormone uptake in the small intestine. Experiments with 
enterocytes are not possible, as intestinal biopsies contain different cell 
types and are contaminated with the intestinal flora. The intestinal model 
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Caco2 (colon carcinoma) is a cell line that in vitro undergoes spontaneous 
enterocytic differentation. This makes it a reliable in vitro model to study 
intestinal absorption, transport and metabolism (41). In chapter 5 we 
provide evidence that there is transport of T3 and T4 in Caco2 cells and 
describe the transport characteristics.
FAcTors INFlueNcING lT4 ABsorPTIoN
The studies on the best time of LT4 intake and the experiments on T4 
uptake by intestinal cells, made it clear that there are many factors 
influencing the absorption of T4. The absorption can be decreased 
by food, beverages, gastrointestinal disorders and several drugs. In 
chapter 6 we give an overview of the latest available literature on this 
subject. Guidelines are given to ensure optimal absorption of LT4. When 
patients have a persistent elevation of TSH levels, despite high doses of 
LT4, it is emphasized that malabsorption by gastrointestinal disorders 
or drugs should be excluded. Finally, pseudo-malabsorption (non-
compliance) is often a diagnostic challenge. A guideline is presented how 
to carefully investigate this clinical problem.
IN PersPecTIve
In chapter 7 we discuss the implications of our clinical studies on daily 
practice. We describe the (inter)national guidelines that have included 
bedtime LT4 intake as an alternative to morning intake. Suggestions for 
further research on QOL in hypothyroidism are posted.
The results of the experiments on T4 and T3 uptake in Caco2 cells are 
discussed, and suggestions on further research are made.
summAry
chapter 8 and 9 are the English and Dutch summary of this thesis, 
respectively.
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summAry
objective Standard drug information resources recommend that 
L-thyroxine be taken half an hour before breakfast on an empty 
stomach, to prevent interference of its intestinal uptake by food or 
medication. We observed cases in which TSH levels improved markedly 
after changing the administration time of L-thyroxine to the late 
evening. We therefore conducted a pilot-study to investigate whether 
L-thyroxine administration at bedtime improves TSH and thyroid 
hormones, and whether the circadian rhythm of TSH remains intact.
Design Patients were studied on two occassions: on a stable regimen 
of morning thyroxine administration and two months after switching to 
night-time thyroxine using the same dose. On each occasion patients 
were admitted for 24 h and serial blood samples were obtained.
Patients We investigated 12 women treated with L-thyroxine because 
of primary hypothyroidism, who used no medication known to interfere 
with L-thyroxine uptake.
measurements Patients were admitted to hospital and blood 
samples were obtained at hourly intervals for 24 h via an indwelling 
catheter. Following this first hospital admission, all women were 
asked to switch the administration time from morning to bedtime or 
vice versa. After 2 months they were readmitted for a 24-h period of 
hourly blood sampling. Blood samples were analysed for serum TSH 
(immunometric assay), FT4 and T3 (competitive immunoassay), T4 and 
rT3 (radioimmunoassay), serum TBG (immunometric assay) and total 
protein and albumin (colourimetric methods).
results A significant difference in TSH and thyroid hormones was 
found after switching to bedtime administration of L-thyroxine. Twenty-
four-hour average serum values amounted to (mean ±SD, morning vs 
bedtime ingestion): TSH , 5.1 ± 0.9 vs 1.2 ± 0.3 mU/l (p < 0.01); FT4, 
16.7 ± 1.0 vs 19.3 ± 0.7 pmol/l (p < 0.01); T3, 1.5 ± 0.05 vs 1.6 ± 0.1 
nmol/l (p < 0.01). There was no significant change in T4, rT3, albumin 
and TBG serum levels, nor in the T3/rT3 ratio. The relative amplitude 
and time of the nocturnal TSH surge remained intact.
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conclusions L-thyroxine taken at bedtime by patients with primary 
hypothyroidism is associated with higher thyroid hormone concentrations 
and lower TSH concentrations compared to the same L-thyroxine dose 
taken in the morning. At the same time, the circadian TSH rhythm 
stays intact. Our findings are best explained by a better gastrointestinal 
uptake of L-thyroxine during the night.
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INTroDucTIoN
Levothyroxine is currently one of the most prescribed medications (1). 
For the widely used oral preparations, enteral absorption of L-thyroxine 
is approximately 70-80% (2-4). The small bowel is the primary site 
of thyroid hormone absorption by a mechanism of translocation 
across the mucosa that remains unclear (5). Interference with 
L-thyroxine absorption has been documented for cholestyramine resin, 
colestipol hydrochloride, sucralfate, iron sulfate, aluminum antacids, 
activated charcoal, raloxifen, food and herbal remedies (2,6). Also, 
a fiber-enriched diet has been shown to have an adverse effect on 
the intestinal absorption of L-thyroxine (7). Therefore, standard drug 
information resources, including manufacturers’ prescribing information, 
recommend that L-thyroxine be taken on an empty stomach in the 
morning. Consequently, hypothyroid patients worldwide are advised to 
take L-thyroxine tablets in the morning half an hour before breakfast. 
However, whether intestinal absorption is better when the stomach is 
empty in the morning or at night has never been studied systematically. 
Recently, we observed several patients whose thyroid hormone profiles 
improved markedly after changing the administration time of L-thyroxine 
to bedtime. This prompted us to further study this phenomenon.
The circadian variation of serum TSH in man is well-documented. The 
serum levels of TSH increase in the evening, reach a maximum near 
sleep onset and are followed by a progressive decrease during the night 
and low values during the day (8-11). The percentage nocturnal rise 
of TSH is 71 ± 40% in healthy controls, and is maintained in euthyroid 
patients on levothyroxine therapy taken in the morning (63 ± 51%) and 
patients with mild hypothyroidism (54 ± 33%) (10), whereas in overt 
hypothyroidism this nocturnal surge disappears.
Changing the administration time of L-thyroxine to bedtime in patients 
with primary hypothyroidism might influence the nocturnal TSH surge 
and the circadian variation of serum TSH. In that case, taking one blood 
sample per day may not represent average hormone levels, as this 
single blood sample may be drawn on completely different moments of 
the hormone cycles.
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Thyroid hormone deiodination by deiodinases type 1, 2 and 3, and 
other pathways of T4 metabolism could also be affected by altering the 
administration time of L-thyroxine.
The aim of this pilot study was, to investigate the effect of changing the 
administration time of L-thyroxine from early morning to bedtime on (1) 
thyroid hormone profiles, (2) the circadian rhythm of TSH and thyroid 
hormones, and (3) thyroid hormone metabolism.
PATIeNTs AND meTHoDs
Twelve women, aged 25-75 yrs (mean 48 yrs), on L-thyroxine treatment 
because of primary hypothyroidism, volunteered for this study. The 
mean dose of L-thyroxine (Thyrax, Organon) was 121 μg, the mean 
body weight 78 kg. None of the patients used medication known to 
interfere with L-thyroxine absorption, nor were they known to have 
gastro-intestinal disease. The cause of hypothyroidism was primary 
(auto-immune) hypothyroidism in 8 subjects; in 3 subjects previous 
radioiodine treatment given because of Graves’ disease and in one 
thyroidectomy because of nodular goitre. All subjects gave written 
consent and the protocol was approved by the local ethics committee.
Patients were admitted to the hospital for 24 h on two separate days, 
with a two-month interval. On the first day all subjects were still taking 
L-thyroxine at their usual time (10 women in the morning, 2 women 
at bedtime). The former were used to taking L-thyroxine half an hour 
before breakfast, between 6:00 and 7:00 a.m. Blood samples were 
obtained at hourly intervals for 24 h via an indwelling catheter, followed 
by rinsing with heparinized saline.
Following this first hospital admission, all women were asked to switch 
the administration time from morning to bedtime at 10:00 p.m. (and 
vice versa from bedtime to morning between 6 and 7 a.m.). After 2 
months they were admitted again for a 24-h period of hourly blood 
sampling. During admission all subjects were ambulant during the day, 
meals were taken at standardized times (7:30 a.m., 12:30 p.m. and 
5:30 p.m.), and they were in bed from 11.00 p.m. to 7.00 a.m.
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Blood samples were immediately centrifuged and stored at 4 °C. Within 
12 h the plasma samples were divided in small aliquots and stored 
at –80 °C until analysis. Serum TSH (normal range 0.4-4.0 mU/l) was 
measured by immunometric assay (Immulite 2000), with a detection 
limit of 0.002 mU/l. The interassay variation was 12.5, 4.6, 5.1, 4.5 
and 6.4% at mean TSH values of 0.02, 1.3, 7.3, 19.0 and 39.0 mU/l, 
respectively. FT4 (normal range 10.0-24.0 pmol/l) and T3 (normal 
range 1.23-2.80 nmol/l) were measured by competitive immunoassay 
(Immulite 2000), T4 (normal range 58-128 nmol/l) and rT3 (normal 
range 0.14-0.34 nmol/l) by radioimmunoassay, serum TBG (normal 
range 12-38 mg/l) by immunometric assay (Immulite 2000), and total 
protein and albumin by colorimetric methods.
Statistical analysis was carried out using ANOVA, paired student t-tests 
and paired-samples t-test for the blood pressure and pulse frequency. 
Significance of diurnal variation (time dependency) of the different 
hormone curves was assessed using a one-way ANOVA with repeated 
measures. Only if ANOVA detected a significant effect of time, a cosinor 
analysis was performed on the data sets of individual patients, using the 
fundamental period (24h). Curve fitting was performed using constrained 
nonlinear regression analysis (SPSS 11.0). Subsequently, only if the 
significance level of the fitted curve was less than 0.05, data were used to 
calculate circadian rhythm parameters (12). Student’s t-test (paired) were 
used to detect significant differences between the curves of the morning 
and evening treatment. For the ANOVA, (paired) t-tests and the cosinor 
analysis, p<0.05 was considered to be a significant difference. In all 
cases, statistics and cosine analysis were done on absolute values. Circular 
statistics were applied for the acrophase data, that is, Jupp’s Phi and S 
for mean angle and angular standard deviation, Mardia–Watson–Wheeler 
Chi-square test for evaluation of acrophase differences between groups 
(13). This was not a randomized double-blind study although hormone 
measurements and statistical analyses were done without information 
about the time of L-thyroxine ingestion.
We asked all patients to fill out forms concerning symptoms of 
hypothyroidism and Quality of Life (QOL) during the periods of morning 
administration and bedtime administration. Firstly, a subjective symptom 
questionnaire which assessed 20 symptoms of hypothyroidism and/
or hyperthyroidism (for example depression, weight gain, cold/heat 
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intolerance, constipation etc.) was obtained (14). Patients scored these 
symptoms as not present (1 point), hardly present (2 points), present 
(3 points), or severely present (4 points). Secondly, a general QOL 
questionnaire (RAND-36) (15) was used to measure health related QOL 
according to 8 subscales. These subscales are: physical functioning, 
role physical functioning, bodily pain, general health perception, role 
emotional functioning, emotional well-being, energy/fatigue and social 
functioning. The scale score ranged from 0-100 for every subscale, with 
a higher outcome meaning a better health status.
resulTs
Serum TSH levels decreased and FT4 and T3 levels increased 
remarkably and significantly after changing the time of L-thyroxine 
ingestion from morning to bedtime (Figure 1). The results of 11 patients 
are given, as it was impossible to gain venous access in one subject. 
Table 1 shows all the 24-hours mean values ± standard deviation 
for TSH, FT4, T3, T4, rT3, the T3/rT3 ratio, albumin and TBG during 
morning and bedtime thyroxine administration.
When levothyroxine is taken in the morning there is an increase in 
serum FT4 after taking the tablet (p<0.05), which is not found after 
taking the tablet at bedtime, as is shown in Figure 1B. Serum rT3 levels, 
the biologically inactive product of inner ring deiodination of T4, did 
not change significantly, and neither did TT4, with time of thyroxine 
digestion. The ratio of active versus inactive thyroid hormone (T3/rT3), 
a parameter which reflects thyroid hormone metabolism by outer ring 
versus inner ring deiodination did not differ between the morning or 
bedtime ingestion of levothyroxine.
TSH decreased and FT4 rose in all patients by changing thyroxine 
ingestion from early morning to bedtime and T3 levels rose in all but 
one subject. A decrease in TSH levels was observed irrespective of initial 
TSH levels. The 24-h mean TSH levels during both the morning and 
bedtime administration of levothyroxine are negatively correlated with 
the 24-h mean FT4 levels (R= -0.64).
 30
0
1
2
3
4
5
6
7
9 12 15 18 21 24 3 6 9
time (hours)
TS
H 
m
U/
L 
LT4 morning
LT4 bedtime
 
0
1
2
3
4
5
6
7
9 12 15 18 21 24 3 6 9
time (hours)
TS
H 
m
U/
L 
m
or
ni
ng
 
(a
ll 
pa
tie
nt
s)
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
m
U/
L 
be
dt
im
e
LT4 morning
LT4 bedtime
12
14
16
18
20
22
9 12 15 18 21 24 3 6 9
time(hours)
FT
4 
pm
ol
/l
LT4
morning
LT4
bedtime
0,2
0,3
0,4
0,5
9 12 15 18 21 24 3 6 9
time (hours)
rT
3 
nm
ol
/l
LT4
morning
LT4
bedtime
1,1
1,3
1,5
1,7
1,9
9 12 15 18 21 24 3 6 9
time(hours)
TT
3 
nm
ol
/l
LT4
morning
LT4
bedtime
95
100
105
110
115
120
125
130
135
140
9 12 15 18 21 24 3 6 9
time (hours)
TT
4 
nm
ol
/l
LT4
morning
LT4
bedtime
3
4
5
6
9 12 15 18 21 24 3 6 9
time (hours)
T3
/rT
3
LT4
morning
LT4
bedtime
15
16
17
18
19
20
21
9 12 15 18 21 24 3 6 9
time (hours)
TB
G
 m
g/
l
LT4
morning
LT4
bedtime
56
58
60
62
64
66
68
70
72
9 12 15 18 21 24 3 6 9
time (hours)
To
ta
l p
ro
te
in
 (g
/l)
LT4 morning
LT4 bedtime
31
32
33
34
35
36
37
38
39
40
41
9 12 15 18 21 24 3 6 9
time (hours)
Al
bu
m
in
 (g
/l)
LT4 morning
LT4 bedtime
A1) A2)
B)
0
1
2
3
4
5
6
7
9 12 15 18 21 24 3 6 9
time (hours)
TS
H 
m
U/
L 
LT4 morning
LT4 bedtime
 
0
1
2
3
4
5
6
7
9 12 15 18 21 24 3 6 9
time (hours)
TS
H 
m
U/
L 
m
or
ni
ng
 
(a
ll 
pa
tie
nt
s)
0,2
0,4
0,6
0,8
1,0
1,2
1,4
1,6
1,8
m
U/
L 
be
dt
im
e
LT4 morning
LT4 bedtime
12
14
16
18
20
22
9 12 15 18 21 24 3 6 9
time(hours)
FT
4 
pm
ol
/l
LT4
morning
LT4
bedtime
0,2
0,3
0,4
0,5
9 12 15 18 21 24 3 6 9
time (hours)
rT
3 
nm
ol
/l
LT4
morning
LT4
bedtime
1,1
1,3
1,5
1,7
1,9
9 12 15 18 21 24 3 6 9
time(hours)
TT
3 
nm
ol
/l
LT4
morning
LT4
bedtime
95
100
105
110
115
120
125
130
135
140
9 12 15 18 21 24 3 6 9
time (hours)
TT
4 
nm
ol
/l
LT4
morning
LT4
bedtime
3
4
5
6
9 12 15 18 21 24 3 6 9
time (hours)
T3
/rT
3
LT4
morning
LT4
bedtime
15
16
17
18
19
20
21
9 12 15 18 21 24 3 6 9
time (hours)
TB
G
 m
g/
l
LT4
morning
LT4
bedtime
56
58
60
62
64
66
68
70
72
9 12 15 18 21 24 3 6 9
time (hours)
To
ta
l p
ro
te
in
 (g
/l)
LT4 morning
LT4 bedtime
31
32
33
34
35
36
37
38
39
40
41
9 12 15 18 21 24 3 6 9
time (hours)
Al
bu
m
in
 (g
/l)
LT4 morning
LT4 bedtime
A1) A2)
B)
31TH profiles with evening LT4
The pattern of the circadian rhythm stayed intact during the morning 
and bedtime administration of levothyroxine, and is almost identical 
(Figure 1, A2). The ANOVA and cosinor analysis showed a significant 
effect of time on all parameters (Table 2) except for T3 (not shown). 
FT4 as well as T4 show a significant difference between the morning 
administration and the bedtime administration in the 24-h mean values 
of the fitted curves, with higher values after the bedtime administration. 
In addition, bedtime administration slightly decreased the relative 
amplitude of their daily rhythms and phase-advanced the timing of 
their acrophase. Daily TSH rhythms were not affected by the timing of 
L-thyroxine intake.
The mean blood pressure was 130/75 mmHg during the morning dosage 
and 127/77 mmHg during the bedtime dosage (NS) and mean pulse rate 
68/min and 65/min, respectively (NS).
The subjective symptom questionnaire showed no change in quality 
of life, with 41.5 ± 9.9 points during the morning administration of 
Table 1
Difference in serum levels of thyroid hormones and their binding proteins, between 
the morning administration and bed time administration of levothyroxine. Data given 
as the 24 hours mean hormonal values ± standard deviation of all 11 patients.
TsH
mu/l
FT4
pmol/l
TT3
nmol/l
TT4
nmol/l
rT3
nmol/l
TT3/rT3 Albumin
g/l
TBG
mg/l
lT4
morning
5.1±0.9 16.7±1.0 1.48±0.05 115.3±8.8 0.34±0.03 4.4±0.38 37.2±1.6 17.3±1.0
lT4
Bedtime
1.2±0.3 19.3±0.7 1.64±0.1 121.2±6.0 0.35±0.03 4.70±0.34 38.2±1.6 17.9±1.0
p-value <0.01 <0.01 <0.01 NS NS NS NS NS
Figure 1.
Thyroid hormones and TSH during the morning administration of levothyroxine (●) 
and the bedtime administration of levothyroxine (∆). Levothyroxine was taken at 
7.00 a.m. ê or at 10.00 p.m ò. A1) Mean TSH serum levels of all patients over 24 
hours. On the same scale. A2) TSH levels on different scales (morning administra-
tion on the left axis, bedtime administration on the right axis) to show that the 
circadian rhythm of TSH stayed intact during the morning and bedtime administra-
tion. B) Mean FT4, TT3, rT3, TT4, TBG, total protein, albumin serum levels and the 
T3/rT3 ratio of all patients over 24 hours.
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Table 2
Results of cosinor analysis for significance of diurnal variation. Only if ANOVA 
detected a significant effect of time, a cosinor analysis was performed on the data 
sets of individual patients (n = the number of patients showing a significant fit). 
Only if the significance level of the fitted curve was less than 0.05 data were used 
to calculate circadian rhythm parameters. The fitted function is defined by its mesor 
(rhythm-adjusted mean), amplitude (50% of the difference between the maximum 
and the minimum of the fitted curve, expressed as a percentage of the mesor), and 
acrophase (time of the maximum). R2, goodness of fit; A, morning administration; B, 
bedtime administration. P-values indicate the result of the paired student t-test on 
the means of A and B. Significant differences are indicated in bold.
Amplitude r2 mesor Acrophase n
TsH
A 39.2 ± 3.6 74 ± 4% 5.6 ± 2.5 02:20 ± 1:25 11 
B 34.9 ± 2.6 71 ± 3% 1.3 ± 0.4 02:25 ± 1:28 10 
n 10 19 10 10 
p-value 0.144 0.51 0.082 0.19 
FT4
A 9.8 ± 1.1 51 ± 6% 17.0 ± 0.8 13:34 ± 1:15 9 
B 5.9 ± 0.7 44 ± 6% 20.2 ± 1.0 10:23 ± 2:05 9 
n 8 8 8 8 
p-value 0.04 0.71 0.006 0.04 
Total protein
A 6.7 ± 0.6 63 ± 5% 66.2 ± 0.9 12:50 ± 1:28 11 
B 5.9 ± 0.8 48 ± 6% 66.4 ± 0.9 13:31 ± 1:35 11 
n 11 11 11 11 
p-value 0.299 0.013 0.72 0.22 
Albumin
A 6.7 ± 0.6 62 ± 6% 37.5 ± 0.6 13:51 ± 1:32 11 
B 5.4 ± 0.8 54 ± 6% 38.4 ± 0.7 13:59 ± 2:18 10 
n 10 10 10 10 
p-value 0.073 0.232 0.186 0.50 
rT3
A 15.5 ± 2.0 58 ± 5% 0.35 ± 0.04 13:26 ± 1:06 11 
B 15.0 ± 0.8 52 ± 5% 0.35 ± 0.04 14:09 ± 1:53 10 
n 10 10 10 10 
p-value 0.580 0.367 0.840 0.98 
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levothyroxine and 39.5 ± 12.2 points during the bedtime administration. 
The RAND-36 questionnaire was also analysed and among the 8 
subscales, only the subscale bodily pain changed significantly in favour 
of the bedtime administration of levothyroxine (p=0.016).
DIscussIoN
This study shows that thyroid hormone profiles improve strikingly 
after changing the time of ingestion of L-thyroxine from early in the 
morning, before breakfast, to late in the evening, at bedtime. This has 
important consequences for the millions of patients who take L-thyroxine 
daily. Taking L-thyroxine at bedtime is also more practical for most 
patients, as it does not coincide with meal times. Switching to bedtime 
administration also proves to be safe and was well-tolerated.
We carried out this pilot study to make sure that the time of L-thyroxine 
administration does not change the circadian rhythm of the serum TSH 
and iodothyronine levels that could result in a systematic error if a 
large, randomized and double-blind study of the effects of the time of 
L-thyroxine ingestion was to be analyzed using a single time of blood 
collection. The marked improvement in T4 availability after changing the 
time of L-thyroxine ingestion from before breakfast to bedtime which is 
Table 2 (continued)
Amplitude r2 mesor Acrophase n
TBG
A 7.8 ± 1.4 42 ± 6% 18.0 ± 0.9 13:00 ± 1:15 11 
B 9.3 ± 1.1 46 ± 6% 18.2 ± 1.1 14:47 ± 2:28 9 
n 9 9 9 9 
p-value 0.419 0.623 0.829 0.12 
T4
A 11.4 ± 1.0 64 ± 5% 110.7 ± 4.4 12:55 ± 0:28 10 
B 7.4 ± 0.7 58 ± 5% 120.6 ± 6.0 11:47 ± 1:40 11 
n 10 10 10 10 
p-value 0.016 0.373 0.051 0.003 
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strongly suggested by this pilot study indeed needs to be confimed in a 
larger randomized trial.
Although the study design seems to be unbalanced as 2 cases took T4 in 
the evening first and then switched to the morning dose, the results of 
the study were similar in both these 2 cases and in the 10 other cases 
and therefore confirm the overall study outcome.
There may be several explanations for our results. Firstly, breakfast 
may interfere with intestinal absorption of L-thyroxine, even if eaten 
half an hour after ingestion of the tablet. If patients take the tablet just 
before bedtime, it is usually hours since their last meal. Secondly, bowel 
motility is slower at night (16), resulting in a more prolonged exposure 
of the L-thyroxine tablet to the intestinal wall and, consequently, in 
a better uptake. The mechanism of transport of L-thyroxine across 
the intestinal wall is unclear. Thus, it is not known whether this is an 
active or a passive process, and what factors influence this process. It 
is possible that this transport process plays a role in the difference in 
L-thyroxine uptake at different times of the day (17, 18).
Thirdly, the production and activity of deiodinases (type 1, 2 and 3) 
is influenced by hyper- and hypothyroidism and certain drugs (19, 
20), but also a circadian rhythm of the deiodinases has recently been 
demonstrated. Type 2 deiodinase for example has a circadian rhythm 
in the central nervous system (21). Other inactivating pathways of T4 
metabolism, such as glucuronidation and sulfation in liver and other 
tissues, may also vary during the day, and contribute to the greater 
bioavailability of thyroxine taken at night. However, one would expect 
changes in the serum T3/rT3 ratio and T4 patterns, if the metabolism 
of thyroid hormones is affected by changing the time of intake of 
levothyroxine, which was not observed.
The bioactivity of TSH also has a circadian variation, with less bioactive 
and differently glycosylated TSH molecules secreted during the night 
(22). This has been used as an explanation for why thyroid hormones do 
not have a nocturnal rise after the TSH surge. Whether the bioactivity 
of TSH is influenced by changing the time of levothyroxine ingestion is 
unknown.
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Although we did not find a correlation in the circadian rhythms of TSH 
and FT4, we found – as expected - a negative correlation of the 24-h 
mean TSH levels with the 24-h mean FT4 levels.
In our study the magnitude and time of the nocturnal TSH surge were 
the same during the morning and bedtime administration of L-thyroxine. 
Although FT4 and T4 showed a different timing in acrophase, this was 
not enough to influence the timing of the TSH acrophase.
The important practical consequence of our findings, namely that the 
circadian rhythm of TSH does not change when switching the time of 
levothyroxine ingestion to bedtime, is that blood sampling for monitoring 
thyroid hormone replacement in patients taking L-thyroxine at bedtime 
need not be changed, i.e. can take place in the morning as is usually 
done.
The circadian rhythm of the binding proteins TBG, total protein and 
albumin is explained by postural changes (with lower levels in supine 
position). Interestingly, we also found a circadian rhythm in FT4, T4 and 
rT3. In previous studies only rapid fluctuations of FT4 were observed, 
without evidence of a circadian rhythm (23).
In conclusion, our study shows that taking L-thyroxine at bedtime 
significantly improves thyroid hormone profiles in patients with primary 
hypothyroidism, whereas the circadian rhythm of TSH remains intact. 
A large double-blinded randomized study will need to be performed to 
confirm our results.
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ABsTrAcT
Background Levothyroxine sodium is widely prescribed to  treat 
primary hypothyroidism. There is consensus that levothyroxine should 
be taken in the morning on an empty stomach. A pilot study showed 
that levothyroxine intake at bedtime significantly decreased thyrotropin 
levels and increased free thyroxine and total triiodothyronine levels. 
To date, no large randomized trial investigating the best time of 
levothyroxine intake, including quality of life evaluation has been 
performed.
methods To ascertain if levothyroxine intake at bedtime instead of in the 
morning improves thyroid hormones levels, a randomized, double-blind, 
crossover trial was performed between April 1, 2007 and November 30, 
2008, among 105 consecutive patients with primary hypothyroidism at 
Maasstad Hospital Rotterdam in the Netherlands. Patients were instructed 
during 6 months to take 1 capsule in the morning and 1 capsule at 
bedtime (one containing levothyroxine and the other a placebo), with a 
switch after 3 months. Primary outcomes were thyroid hormone levels; 
secondary outcome measures were creatinine and lipid levels, body mass 
index, blood pressure, heart rate and quality of life.
results Ninety patients completed the trial and were available for 
analysis. Compared with morning intake, direct treatment effects when 
levothyroxine was taken at bedtime were a decrease in TSH level of 
1.25 mU/L (95% confidence interval (CI) 0.6-1.89 mIU/L, p<0.001), 
an increase in FT4 by 0.07 ng/dl (0.02–0.13 ng/dL, p=0.01) and an 
increase in TT3 by 6.5 ng/dl (0.9-12.1 ng/dL, p=0.02). Secondary 
outcomes, including the QOL-questionnaires (36-item Short Form Health 
Survey, Hospital Anxiety and Depression Scale, 20-item Multidimensional 
Fatigue Inventory and a symptoms-questionnaire), showed no significant 
changes between the morning vs. bedtime intake of levothyroxine.
conclusions Levothyroxine taken at bedtime significantly improved 
thyroid hormone levels. Quality of life variables and plasma lipid 
levels showed no significant changes with bedtime vs morning intake. 
Clinicians should consider prescribing levothyroxine intake at bedtime.
Trial Registration: isrctn.org, Identifier: ISRCTN17436693 (NTR959).
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INTroDucTIoN
Because the prevalence of primary hypothyroidism is high in the 
general population (1,2), levothyroxine is one of the most prescribed 
medications. The absorption of levothyroxine takes place in the small 
bowel and is approximately 70-80% (3). There is consensus that 
levothyroxine should be taken before breakfast to prevent interference 
of its intestinal uptake by food or other medication (4-10). In our clinics 
we observed several patients whose thyroid hormone levels improved 
markedly after changing the scheduled intake of levothyroxine to 
bedtime. A pilot confirmed this observation among 11 patients (11). 
The mean (SD) plasma thyrotropin (TSH) level significantly decreased 
from 5.1 (0.9) to 1.2 (0.3) mIU/l and free thyroxine (FT4) and 
triiodothyronine (T3) levels increased when levothyroxine was taken 
at bedtime. The circadian pattern of the TSH rhythm remained intact, 
which was important regarding the time of blood sampling for TSH levels 
to monitor levothyroxine therapy.
Accordingly, we conducted a randomized double-blind crossover trial 
to confirm whether levothyroxine taken at bedtime leads to lower TSH 
and higher FT4 and T3 levels. Hypothyroidism can have major effects 
on health and quality of life (QOL), as it is associated with fatigue, 
weight gain, cold intolerance, depression, neuromuscular symptoms, 
diastolic dysfunction and impairment of renal function (12-15). It is 
also associated with risk factors for cardiovascular disease, such as 
hyperlipidemia, hyperhomocystinemia and arterial hypertension, notably 
in case of insufficient thyroid hormone supplementation (16,17).
The primary objective of this study was to determine whether a change 
occurred in TSH and thyroid hormone levels when levothyroxine was 
taken at bedtime vs in the morning. We further investigated whether 
a bedtime regimen would affect creatinine and lipid levels, body mass 
index (BMI), heart rate and QOL.
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meTHoDs
study participants
A randomized double-blind crossover trial was performed in consecutive 
patients with primary hypothyroidism that visited our clinics. The 
patients had to be older than 18 years of age and be on a stable dose 
of levothyroxine for at least 6 months. Patients with a gastrointestinal 
disorder, with thyroid carcinoma and pregnant women were excluded. 
Also patients who used intercurrent medication known to interfere with 
the uptake of levothyroxine were excluded (4,7-10). The Medical Ethics 
Committee of the Maasstad Hospital Rotterdam approved the study 
protocol and written informed consent was obtained from each patient.
randomization and treatment
After informed consent had been obtained patients were randomized 
to start the study period with either levothyroxine in the morning (and 
placebo at bedtime) or levothyroxine at bedtime (and placebo in the 
morning). After 3 months patients were switched from levothyroxine 
in the morning to placebo and vice versa for another 3 months. Double 
blind study medication was provided by the hospital pharmacy, which 
performed the actual randomization. Commercial Thyrax Duotab tablets 
0,100 mg were used and reformulated as capsules with lactose 1H2O 
as the single excipient (in compliance with GMP guidelines, annex 13, 
Manufacture of investigational medicinal products). Every patient got 
capsules containing a similar dose of levothyroxine as before entry into 
the trial. Placebo and levothyroxine capsules were optically identical. 
Patients were instructed by a research nurse to take the morning 
capsule on an empty stomach half an hour before breakfast and the 
bedtime capsule at night just before going to bed.
Data collection, follow up and compliance
At baseline and every 6 weeks people were seen in our clinics by a 
research nurse. At these visits blood samples were taken to determine 
plasma TSH, FT4, T3, creatinine and lipids and blood pressure, heart 
rate and body weight were measured. Also the remaining capsules in 
the containers were counted to check for compliance. Quality of life 
questionnaires were completed by the patients at baseline, at 3 months 
and at the end of the study.
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Blood sampling
Blood samples were drawn in the morning before the planned visit 
to the research nurse. Capsules were not withheld on the day of 
bloodsampling. Serum TSH levels (reference range 0.4-4.0 mU/l) were 
measured by immunometric assay (Immulite 2000, DPC Nederland, 
Breda, The Netherlands), with a detection limit of 0.002 mU/l. FT4 
(reference range 10-24.0 pmol/l, equivalent with 0.78-1.86 ng/dl) and 
T3 (reference range 1.23-2.80 nmol/l, equivalent with approximately 
80-182 ng/dl) were measured by competitive immunoassay (Immulite 
2000). Creatinine and lipid levels were measured on a Dimension RxL 
machine (Dade-Behring).
quality of life and Patient preference
Three different quality of life (QOL) questionnaires (SF-36, HAD, MFI-20) 
and a specific questionnaire for symptoms of hypo- and hyperthyroidism 
were completed by the patients at baseline, at 3 months and at the 
end of the study. Patients completed the questionnaires under the 
supervision of a research nurse. The SF-36/RAND-36 (the 36-Item 
Short Form Health Survey questionnaire) is a general quality of life 
questionnaire that comprises 8 scales (18). The Hospital Anxiety 
and Depression Scale (HADS) consists of 14 items pertaining to 
anxiety and depression (19). The 20-Item Multidimensional Fatigue 
Index (MFI-20) measures 5 different dimensions of fatigue (20). The 
specific questionnaire for thyroid symptoms assesses 14 symptoms of 
hypothyroidism and 6 symptoms of hyperthyroidism (21). At the end 
of the trial, before the randomization code was broken, patients were 
asked during which period of the trial they had felt better. After the 
trial had ended patients were free to choose at what time they wanted 
to continue taking levothyroxine, in the morning or at bedtime. One 
year after the trial we asked every patient at what time they took the 
levothyroxine tablet.
statistical analysis
The primary end point was a change in thyroid hormone parameters 
(TSH, FT4, TT3) between 12 weeks of morning thyroxine and 12 
weeks of bedtime levothyroxine. Secondary end points were changes 
in the quality of life (measured by 3 questionnaires) and in the thyroid 
symptom score, body mass index (BMI), heart rate and serum lipid and 
creatinine levels.
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The direct treatment effect in all parameters was measured by 
performing an independent samples t-test between the differences 
of week 12 and week 24 in the first group (started with morning 
thyroxine) and the second group (started with bedtime thyroxine) (22). 
The presence of a carryover effect, from one period to the other, was 
measured by performing a independent samples t-test on the sum of 
the parameters at 12 and 24 weeks in each individual. All p-values 
were two-sided and have not been adjusted for multiple testing. All 
calculations were done using SPSS 17.0 for Windows.
To calculate the sample size we assumed that a difference in TSH of 1.0 
mU/l between morning and bedtime ingestion of levothyroxine would 
be clinically relevant. From our previous results in the pilot study we 
calculated that the standard deviation of the difference between morning 
and bedtime administration would be between 2.5 and 3.0 mU/l. Based 
on these calculations, a sample size of 75 patients would give at least 
80% power to detect a significant difference of 1 mU/l between the 
morning and bedtime administration.
resulTs
study participants and treatment
From April 2007 through June 2008, a total of 141 patients were 
assessed for eligibility. Eventually 105 patients met the inclusion criteria 
and gave written informed consent. Reasons for exclusion were the 
intercurrent use of interfering medication (n=11), a history of thyroid 
carcinoma (n=3), an unusual dose of levothyroxine (n=6), treatment 
for breast cancer (n=1) and Addison’s disease (n=1). Of the randomized 
patients 15 withdrew their consent shortly after entry into the trial 
and have only results at baseline. The baseline characteristics of these 
patients did not differ from the patients who completed the trial. Data 
for analysis of the 24 weeks were available for 90 (86%) of the patients 
who enrolled the trial, of whom 47 started with levothyroxine intake in 
the morning and placebo at bedtime, and 43 started with levothyroxine 
at bedtime and placebo in the morning (Figure 1).
The baseline characteristics of the two groups are given in Table 
1. There was a difference in the amount of male patients, dose of 
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levothyroxine and TSH between the two groups. On average, patients 
missed 1.3 ± 6 capsules in the morning and 1.9 ± 10.1 capsules in 
the evening during the 24 weeks of the trial (p= 0.54). As there were 
no severe symptoms related to hypo- or hyperthyroidism, none of the 
patients required an adaptation of the levothyroxine dose during the 
trial.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
141 patients assessed for eligibility 
22 patients did not meet entry criteria 
14 patients did not give consent 
105 patients underwent randomization 
 
 
53 started with morning LT4 52 started with bedtime LT4 
6 patients stopped and did 
not have adequate data for 
analysis of the primary 
outcomes 
3 had complaints (1      
swollen eyelids, 2 felt  
worse) 
1 was used to bedtime 
intake 
  2 found protocol too time 
  consuming 
9 patients stopped and did 
not have adequate data for 
analysis of the primary 
outcomes 
1 had complaints (felt 
worse) 
1 could not follow 
protocol 
  7 found protocol too time 
  consuming 
47 patients had adequate data for 
analysis of the primary outcomes 
43 patients had adequate data for 
analysis of the primary outcomes 
Figure 1. Flowchart of the study, showing disposition  of patients from screen-
ing to study completion Consecutive patients with primary hypothyroidism that vis-
ited our clinics were assessed for eligibility. Exclusion criteria were a gastrointestinal 
disorder, thyroid carcinoma and pregnancy. LT4 denotes thyroxine.
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Primary outcomes
The results of the primary outcomes are shown in Table 2 and Figure 2. 
In the group that received morning levothyroxine first, mean TSH (SD) 
dropped from 2.66 (2.53) mU/l at the end of the morning intake period 
to 1.74 (2.43) mU/l at the end of the bedtime intake period. In contrast, 
in the group that received bedtime levothyroxine first, TSH increased 
from 2.36 (2.55) mU/l at the end of the bedtime intake period to 3.86 
(4.02) mU/l at the end of the morning intake period. When the overall 
changes were compared between the two groups, bedtime levothyroxine 
intake was found to have a direct treatment effect with a decrease 
Table 1 Baseline characteristics of the patients with adequate data for 
analysis of the primary outcomes
SI conversion factors: To convert TSH level to micrograms per liter, multiply by 1.0; 
free thyroxine (FT4) level to picomoles per liter, multiply by 12.871; total T3 level to 
nanomoles per liter, multiply by 0.0154. *The body-mass index is the body weight in 
kilograms divided by the square of the height in meters.
morning lT4 
first (n=47)
Bedtime lT4 
first (n=43)
Age (yr) 48 (11) 48 (13)
Male sex (no. of patients) 13 7
Body mass index* 29.1 (20.0-40.1) 27.9 (19.8-41.0)
Etiology of hypothyroidism (no.of patients)
Hashimoto’s 26 26
I131 17 17
Thyroidectomy 3 0
Radiotherapy neck 1 0
Duration hypothyroidism (yrs) 3 (0.5-25) 2 (0.5-21)
Dose thyroxine (mcg) 125 (50-200) 100 (50-250)
TSH (mU/l) 1.5 (1.7) 3.3 (3.0)
FT4 (ng/dl) 1.58 (0.26) 1.50 (0.27)
T3 (ng/dl) 132.9 (30.7) 122.0 (38.1)
Patients that used other medication (no. of patients) 26 25
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Figure 2. Thyroid hormone levels after 6 and 12 weeks of morning or bedtime 
intake of thyroxine
Mean TSH, FT4 and TT3 levels after 6 and 12 weeks of morning (blue) or bedtime 
(red) intake of thyroxine in the two randomized groups (started with morning () 
vs bedtime () thyroxine). The normal range for TSH is 0.4 to 4.0 mU per liter. The 
normal range for FT4 is 0.78 to 1.86 ng per deciliter. The normal range of T3 is 80-
182 ng per deciliter.
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in TSH by 1.25 mU/l (95% confidence interval, CI, 0.6-1.89 mU/l, 
p<0.000) relative to morning levothyroxine intake.
FT4 (SD), in the group that received morning levothyroxine first, 
increased from 1.48 (0.24) ng/dl at the end of the morning intake 
period to 1.59 (0.33) ng/dl at the end of the bedtime intake period. In 
the group that received bedtime levothyroxine first, FT4 decreased from 
1.54 (0.28) ng/dl to 1.51 (0.2) ng/dl. Thus bedtime intake resulted in 
a direct treatment effect with an increase in FT4 by 0.07 ng/dl (95% CI 
0.02-0.13, p=0.01) relative to morning intake.
Changes in TT3 were similar to those in FT4. In the group that received 
morning levothyroxine first, TT3 (SD) increased from 121.2 (28.1) 
ng/l to 127.0 (31.6) ng/dl. And in the group that received bedtime 
levothyroxine first, TT3 dropped from 128.4 (30.6) ng/dl to 121.9 (36.3) 
ng/dl. Here the direct treatment effect of bedtime levothyroxine was an 
increase in TT3 by 6.5 ng/dl (95% CI 0.9-12.1, p=0.024). No first-order 
carry over effect was found for TSH, FT4 or TT3.
secondary outcomes
There were no differences between serum creatinine and lipid levels, 
blood pressure, heart rate and BMI between the two regimens (Table 2).
The SF-36 questionnaire, the HAD- scale and the MFI-20 did not show 
differences in their subscales or total scores between the period of 
morning versus bedtime intake of levothyroxine (Table 3). Furthermore, 
the symptoms indicative of hypothyroidism showed no change between 
the two periods, despite the improved thyroid hormone profiles. Neither 
was there a difference in symptoms of hyperthyroidism (Table 3).
Patient preference
When asked at the end of the trial (before the randomization code was 
broken), 34 of the 90 patients preferred the period in which the morning 
capsule contained levothyroxine, 31 patients the period in which the 
bedtime capsule contained levothyroxine; 25 persons could not indicate 
a preference. More than half of the patients still preferred the bedtime 
intake of levothyroxine one year after the trial was completed.
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commeNT
We performed this large randomized double-blind trial in 90 patients 
to address the question if levothyroxine taken at bedtime instead of in 
the morning improves thyroid hormone levels. The primary outcomes 
show a decrease in TSH level by 1.25 mU/l and increased FT4 and TT3 
levels when levothyroxine is taken at bedtime. Despite the change in 
thyroid hormone levels, the quality of life did not differ. The intake of the 
levothyroxine tablet at bedtime instead of in the morning could be more 
convenient for patients, as they do not have to postpone breakfast. 
After our study was completed more than half of the patients decided to 
continue with the bedtime intake of levothyroxine.
How can the effects on the bioavailability of levothyroxine be explained? 
An interval of 30 minutes between taking levothyroxine and breakfast 
may be too short to prevent interference with the gastrointestinal 
absorption of levothyroxine. Moreover, many patients drink coffee in the 
morning, often instead of breakfast (6), or may take other medication 
which interferes with levothyroxine absorption. On the contrary, most 
patients in the study stated that they had taken no food or snacks for 
several hours before bedtime, this being their usual routine. Bowel 
motility is slower at night, resulting in a more prolonged exposure 
of levothyroxine to the intestinal wall and, consequently in better 
availability (23). Furthermore, basal gastric acid secretion is highest in 
the late evening and lowest in the morning (24). An acidic environment 
promotes the absorption of levothyroxine (25). These circadian 
differences in gastro-intestinal function could be a pathophysiological 
explanation for our findings.
Thyroid hormone level changes did not translate into a change in the 
quality of life. There are various explanations for this observation. 
Patients with hypothyroidism taking adequate doses of levothyroxine 
(i.e. those whose TSH level is in the reference range) can still have 
significant impairment in psychological well being and cognitive function 
compared with control subjects (26, 27). This could be related to their 
knowing that they have a chronic illness or are overweight. Weight 
gain and inability to lose weight are known to occur in patients with 
treated hypo- and hyperthyroidism (28, 29). In our study, BMI was 
high in both study groups. A trial investigating T3 supplementation 
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showed that improved QOL was limited to a subgroup of patients with 
suppressed TSH levels who had lost weight (30). Based on the results 
of population studies (2, 28) it has been suggested that the treatment 
goal in patients with hypothyroidism should be a TSH level of 1.0 mU/l 
or lower. On the other hand, plasma thyroid hormone levels may not 
be representative of thyroid hormone levels at the tissue level (e.g. 
the brain); therefore, they would be unrelated to QOL (31,32). Finally, 
newly discovered thyroid hormone metabolites like thyronamine (T1), 
that are not replaced by levothyroxine could influence QOL (33); and 
the presence of an autoimmune disorder (Hashimoto’s thyroiditis), may 
have an effect on the brain and QOL, independent from thyroid hormone 
supplementation (34).
The primary outcomes of this study are consistent with the results of a 
pilot study we performed earlier (11). Two other studies on the timing 
of levothyroxine have been published. In a retrospective chart review in 
15 nursing home residents, Elliott showed a nonsignificant decrease in 
TSH levels when levothyroxine intake was switched from after breakfast 
to midnight (35). The results of that non-randomized trial confirm the 
results of our study. A 3-period cross-over design (36) study showed 
higher TSH values when levothyroxine was taken at bedtime instead 
of before breakfast, but no change in FT4 and TT3 as observed in our 
study. The exclusion criteria for that study were extensive, and of the 
eligible patients only 19% were interested in participation. The study 
also included patients with thyroid cancer whose TSH levels were 
maintained at lower levels than the rest of the population. Therefore, we 
think that the generalizability of our study for the treatment of primary 
hypothyroidism is better. The lower TSH levels with levothyroxine 
intake before breakfast compared to bedtime intake in that study could 
be explained by the larger interval between levothyroxine intake and 
breakfast (60 min instead of 30 min). Also, in our study most patients 
stated that they had nothing (or only a small snack) to eat several 
hours before bedtime, which differs across cultures. In all the studies 
performed on the timing of levothyroxine, intake on an empty stomach 
seems to result in the best absorption of levothyroxine. Our study 
shows that if this ‘fasting’ regimen can be achieved at bedtime, thyroid 
hormone levels are better than with levothyroxine intake 30 minutes 
before breakfast.
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The study  design has potential limitations including order and sequence 
effects. We did not find a first-order carry over effect between the two 
periods, but did not look at other order or sequence effects. It should 
also be noted that this was a single-site study in the Netherlands, 
where eating habits might be different from habits in other countries or 
cultures.
Based on the results of our study,  clinicians should inform hypothyroid 
patients that levothyroxine intake at bedtime is a good alternative for 
levothyroxine intake in the morning, provided that levothyroxine is taken 
on an empty stomach. Notably in case patients do not reach normal 
TSH and/or FT4 levels with morning levothyroxine intake, a switch to 
bedtime is recommended. Recommendations on timing of levothyroxine 
intake and on uptake interference by food are found in few guidelines 
about the management of hypothyroidism (37,38). Drug information 
resources and guidelines need revision in this respect.
In conclusion, bedtime intake of levothyroxine in our study significantly 
improved thyroid hormone levels. This might be explained by better 
gastrointestinal availability at night or less interference by food and/
or medications. For many patients, as shown in this study, the bedtime 
administration is more convenient. Clinicians should inform their patients 
about the possibility of taking levothyroxine at bedtime. A longer period 
of bedtime levothyroxine therapy may be required for a change in 
quality of life to occur.
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ABsTrAcT
objective Many patients treated for primary hypothyroidism have 
an unexplained reduced quality of life (QOL). We studied the relation 
between QOL and various parameters in treated hypothyroid patients.
Design and methods QOL analysis was done in 90 consecutive patients 
(77.8% female) treated for primary hypothyroidism. QOL was measured 
by the questionnaires SF-36, HADS and MFI20. Post hoc analysis was 
performed on the relation of QOL at baseline and BMI, thyroid hormones 
and other serum values. QOL in patients was also compared to the 
general population.
results QOL was decreased compared to the general population. We 
found an inverse relationship between QOL and BMI. A relationship 
between QOL and serum thyroid parameters or auto-antibodies could 
not be found. Higher SHBG levels corresponded with a better QOL, 
which is explained by the negative association of SHBG with body weight 
and BMI.
conclusions A decreased QOL in hypothyroid patients on thyroxine 
treatment is related to a higher body weight (BMI). Weight gain needs 
more attention in the treatment of hypothyroidism.
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INTroDucTIoN
Primary hypothyroidism is a frequent disorder in the general population, 
with a prevalence between 2% and 3% (1, 2). The symptoms of 
hypothyroidism vary widely and are related to a decreased function 
of the brain, muscles, heart and kidney (3-8). Restoration of these 
functions is achieved by treatment with levothyroxine (LT4) (3,5,8) , 
which markedly improves the signs and symptoms of hypothyroidism.
However, numerous patients treated for primary hypothyroidism with 
LT4, still complain of a reduced quality of life (QOL), despite serum 
thyroid hormone (TH) levels within the reference range (9, 10). A large 
study from western England showed that the QOL in a group of treated 
hypothyroid patients was indeed lower compared to controls of similar 
age and sex (9). In a study in Amsterdam in 141 hypothyroid patients, 
cognitive functioning, mental health and vitality were lower compared to 
a Dutch reference group (11).
There is no good explanation for the decreased QOL in hypothyroid 
patients who are euthyroid on LT4 treatment. It seems plausible that 
there is a correlation between QOL and thyroid parameters (TSH, FT4 
and T3). Bearing this in mind, it has been attempted to improve QOL 
in treated patients, by e.g. aiming at a lower serum TSH level during 
treatment (12), by adding liothyronine (LT3) substitution to LT4 (13, 
14), or by making small changes in the LT4 dose (15). Until now these 
attempts have not resulted in an improvement in well-being.
Another aspect in the treatment of hypothyroidism is that serum TH 
levels may not represent TH levels in different tissues. In a study by 
Escobar-Morreale in hypothyroid rats, no single dose of T4 or T3 could 
restore euthyroidism in all tissues at the same time (16), probably 
because of varying expression and function of TH transporters and 
deiodinases. Sex hormone binding globulin (SHBG) is known to be a 
marker of hepatic TH state (17) and could be a useful parameter of 
thyroid hormone status at tissue level.
As most patients with hypothyroidism in iodine-replete areas have auto-
immune thyroiditis (18), auto-immunity per se could also be a cause of 
reduced QOL. A correlation between thyroid auto-antibodies and mood 
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and depression has already been described by some authors (19, 20). 
Other factors, however, that we are still unaware of, could contribute to 
the reduction in QOL of our hypothyroid patients.
We recently performed a double-blind randomized cross-over trial of 
the effects of morning versus bedtime LT4 intake (21). During the trial 
thyroid hormone parameters changed within the same patient, with 
fluctuations just within or near the reference ranges. This is comparable 
to the average outpatient situation, where patients come to ask for the 
results of the laboratory tests. Often, based on the outcomes of these 
test the dosage of the thyroid hormonal supplementation is adapted. 
QOL in our patients, however, did not change, despite the changes 
in thyroid hormone levels (21). During the trial thyroid parameters, 
markers of auto-immunity, vital parameters and QOL were assessed. 
This enabled us to investigate the correlation of these parameters with 
QOL in patients with primary hypothyroidism. In the discussion we will 
also review the literature on this subject.
suBjecTs AND meTHoDs
subject selection and data collection
A double-blind randomized cross-over trial over a period of 6 
months, was performed in consecutive patients with treated primary 
hypothyroidism in our outpatient clinic, to evaluate the effect of morning 
versus bedtime LT4 intake. The results of this trial were published earlier 
(21). In brief, patients older than 18 years of age and on a stable dose 
of LT4 for at least 6 months were included. During the first 3 months 
patients took LT4 in the morning and placebo at night and switched to 
bedtime LT4 and morning placebo for another 3 months (or vice versa). 
At inclusion all patients were clinically assessed by an internist. The 
medical ethics committee of the Maasstad Hospital approved the study 
protocol, and written informed consent was obtained from each patient.
quality of life
QOL was analysed by Short form-36 (SF-36), Hospital Anxiety and 
Depression Scale (HADS) and Multidimensional Fatigue Inventory 
(MFI-20). Data at baseline are presented here, as our previous data (21) 
already showed that QOL did not change during the trial with morning 
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versus bedtime LT4 intake. Analyses at 3 and 6 months were performed 
but showed the same results.
Short-form 36 (SF-36) SF-36 is a general QOL questionnaire that 
comprises 8 scales: physical functioning, social functioning, role 
limitations (physical problems), role limitations (emotional problems), 
mental health, vitality, pain and general health perception. Scores per 
scale range from 0 to 100, the highest score indicating the best state of 
health (22).
Hospital Anxiety and Depression Scale (HADS) The HADS consists of 14 
items pertaining to anxiety and depression. Scores for the anxiety and 
depression subscale range from 0-21 and for the total score from 0-42. 
A higher score reflects more severe anxiety and depression (23).
Multidimensional Fatigue Index (MFI-20) The MFI-20 contains 20 
statements to assess fatigue. From these statements 5 different 
dimensions of fatigue are calculated: general fatigue, physical fatigue, 
reduced activity, reduced motivation and mental fatigue. Scores vary 
between 0 and 20. Higher scores correlate with more fatigue (24).
QOL scores at baseline were compared to scores in healthy control 
subjects (n=440) derived from previous studies in Leiden University 
Medical Center (a hospital in the same region as Rotterdam) on pituitary 
disorders (25). In addition to this control group, we used reference 
data from healthy subjects of the Dutch and West-European population, 
obtained from studies reporting normal age-adjusted values (22, 26, 27).
Blood sampling
Serum TSH levels (reference range 0.4-4.0 mU/l) were measured by 
immunometric assay (Immulite 2000, DPC, Breda, The Netherlands), 
and FT4 (reference range 10-24 pmol/l, equivalent with 0.78-1.86 ng/dl) 
and T3 (reference range 1.23-2.80 nmol/l, equivalent with 80-182 ng/
dl) by competitive immunoassay (Immulite 2000).
Sex hormone binding globulin (SHBG), a marker of hepatic TH status 
(reference range men 14.5-48.4 nmol/l, premenopausal women 26.1-
110 nmol/l, postmenopausal women 14.1-68.9 nmol/l), was measured 
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by immunoassay (Cobas 6000, Roche Diagnostics, Almere, The 
Netherlands).
Anti-thyroid peroxidase (TPO) antibodies were measured by ELISA 
(ImmunoCAP, Phadia AB, Uppsala, Sweden; >60 IU/l considered 
positive) and anti-TSH receptor (TSHR) antibodies by radio-receptor 
assay (BRAHMS. Diagnostica GmbH, Berlin, Germany; >14 U/l 
considered positive). As auto-immune hypothyroidism is often 
associated with other autoimmune disorders, we also tested for 
antibodies to parietal cells (PC), present in pernicious anaemia, by ELISA 
and immunofluorescence (Phadia AB; >15 U/l considered positive), and 
antibodies to tissue transglutaminase (tTG), present in celiac disease, by 
ELISA (ImmunoCAP, Phadia AB; >10 U/ml considered positive).
statistical analysis
All calculations were done using SPSS 20.0 for Windows. All p-values 
were two-sided. Multiple associations between QOL and various 
parameters were studied in retrospect, because of which correction 
for multiple testing was difficult and was not performed. We used 
independent samples t tests (equal variances not assumed) to compare 
patient and control data. Literature reference data used were weighted 
means according to the age distribution in our cohort and an unpaired 
t test was used to compare means. The thyroid parameters were 
categorized in quartiles and SHBG and BMI in tertiles before univariate 
ANOVA analysis. As SHBG reference values vary with sex and age 
(men/women, below/ above 50 years of age), patients were divided in 
tertiles (‘low’, ‘normal’ or ‘high’ SHBG) per category. To investigate the 
relationships of QOL with TH, SHBG and BMI, a one-way ANOVA was 
performed (p value for trend). Linear regression analysis was performed 
on the relation between QOL and BMI, unadjusted and adjusted for age, 
sex and TSH.
resulTs
From April 2007 through June 2008, 90 patients with primary 
hypothyroidism were included in the trial and had adequate data for 
analysis. The mean age was 48 yr (SD 11.7), mean BMI 29.1 kg/m2 (SD 
5.1) and 77.8% was female (Table 1).
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qol in the study population
QOL at baseline was impaired on all scales, as is shown in Table 2. There 
was no difference in QOL with morning or bedtime intake of LT4, as was 
described in our previous paper (21). There was no difference in QOL 
according to the etiology of the hypothyroidism or duration of treatment 
(< 1 year, 1-5 years, >5 years) (data not shown).
qol and thyroid hormone parameters
QOL measured by the 3 questionnaires was not dependent on 
serum TSH, FT4 (Table 3) and T3 (data not shown). As described in 
our previous paper (21), QOL scores did not change with morning 
or bedtime LT4 intake, despite the significant change in thyroid 
parameters.
Table 1 Baseline characteristics of treated hypothyroid patients (n=90).
I131 (radioactive iodide therapy), a-TPO (anti-thyroid peroxidase), a-TSHr (anti-
TSHreceptor), a-PC (anti-parietal cells), a-tG (anti-transglutaminase).
Age, mean (SD), y 48 (11.7)
Female (%) 77.8
BMI, mean (SD) 29.1 (5)
Duration hypothyroidism, median (range), y 2.5 (0.5-25)
Cause hypothyroidism, No.
Autoimmune (Hashimoto) 52
I131 34
thyroidectomy 3
neck radiation 1
Dose LT4, median (range), µg 125 (50-250)
TSH, mean (SD), mU/l 2.38 (2.55)
FT4, mean (SD), pmol/l 19.8 (3.40)
T3, mean (SD), nmol/l 1.96 (0.53)
a-TPO, no. (%) 61 (68)
a-TSHr, no. (%) 10 (11)
a-PC, no. (%) 12 (13)
a-tG, no. (%) 0 (0)
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qol and BmI
BMI in the study population (BMI 29.1 kg/m2) was higher than in the 
general Dutch population (mean BMI women 25.1 kg/m, mean BMI 
men 26.0 kg/m) (29). QOL decreased with increasing body weight 
and, consequently, an increasing BMI in 11 out of 15 subscales of QOL 
(Table 4 and Supplemental Figure 1). The SF-36 questionnaire revealed 
more problems with physical functioning, role limitations due to physical 
problems, vitality, pain and general health at a higher BMI. The HADS 
questionnaire showed higher scores for depression, not anxiety. The 
Table 2 qol in study population compared to controls and reference 
data.
QOL scores at baseline were compared to scores in healthy control subjects derived 
from previous studies in Leiden University Medical Center (a hospital in the same re-
gion as Rotterdam) on pituitary disorders (25). In addition to this control group, we 
used reference data from healthy subjects of the Dutch and West-European popula-
tion, obtained from studies reporting normal age-adjusted values (22, 26, 27)
study 
population 
(n=90)
mean (sD)
controls 
(n=440)
mean (sD) P value1
Age-adjusted 
reference 
values*
mean P value2
sF-36
•Physical functioning 64 (19) 88 (17) <0.001 81 <0.001
•Social functioning 69 (26) 88 (19) <0.001 87 <0.001
•Role limits physical 60 (41) 84 (31) <0.001 79 <0.001
•Role limits emotional 76 (39) 87 (29) 0.01 85 0.03
•Mental health 68 (19) 77 <0.001
•Vitality 51 (22) 67 <0.001
•Pain 74 (26) 86 (19) <0.001 80 0.047
HAD
•Anxiety 6.7 (4.3) 4.1 (3.2) <0.001 4.99 0.001
•Depression 5.4 (4.0) 2.8 (2.9) <0.001 3.52 <0.001
Total 12 (7.6) 6.8 (5.3) <0.001 8.41 <0.001
mFI-20
•General fatigue 12.6 (5.2) 8.5 (4.0) <0.001 9.9 <0.001
•Physical activity 12.6 (4.9) 7.6 (3.7) <0.001 8.8 <0.001
•Reduced activity 11 (4.4) 7.2 (3.5) <0.001 8.7 <0.001
•Reduced motivation 10.2 (4.2) 7.3 (3.4) <0.001 8.2 <0.001
•Mental fatigue 10.4 (5.2) 7.8 (3.9) <0.001 8.3 <0.001
P value1 Patients compared with controls
P value2 Patients compared with literature reference data
* Derived from Refs 22, 26, 27
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MFI-20 questionnaire showed more fatigue at a higher BMI on all 5 
different dimensions of fatigue. There was no relation between etiology 
of hypothyroidism or duration of treatment and BMI (data not shown).
No relationship was found between BMI and the thyroid parameters. 
Adjusting for the confounding factors age, sex and TSH did not change 
the relation between QOL and BMI as assessed by linear regression 
analysis (Supplemental Table 1).
Table 3 TsH (mu/l) and FT4 (pmol/l) levels at baseline in quartiles 
related to qol in treated hypothyroid patients
TsH < 0.72 0.72 <TsH < 1.5 1.5 < TsH < 3.3 TsH > 3.3 p-value
for trendn=22 n=23 n=23 n=22
mean (sD) mean (sD) mean (sD) mean (sD)
sF-36 questionnaire
Physical functioning 66 (22) 59 (18) 65 (20) 65 (17) 0.95
Social functioning 67 (24) 63 (26) 82 (22) 65 (28) 0.61
Role-physical 65 (42) 53 (42) 62 (44) 62 (39) 0.99
Role-emotional 85 (34) 68 (44) 80 (37) 70 (38) 0.37
Emotional wellbeing 70 (17) 62 (20) 77 (13) 62 (22) 0.66
Vitality 52 (19) 42 (23) 58 (25) 50 (18) 0.53
Pain 76 (30) 77 (23) 72 (27) 74 (26) 0.69
General health 55 (24) 53 (22) 58 (21) 55 (22) 0.92
HADs
Depression 4.8 (3.7) 6.3 (4.4) 4.7 (3.3) 5.8 (4.1) 0.69
Anxiety 6.2 (41) 7.4 (5.0) 5.6 (4.2) 7.4 (3.9) 0.68
Total 11.0 (7.2) 13.7 (8.9) 10.2 (6.7) 13.0 (7.2) 0.72
mFI-20
General fatigue 13.1 (5.5) 14.4 (4.1) 9.8 (5.5) 13.1 (4.5) 0.32
Physical fatigue 12.4 (5.1) 14.0 (4.1) 11.0 (5.7) 13.0 (4.6) 0.82
Mental fatigue 11.1 (5.4) 11.4 (4.2) 9.2 (5.4) 9.8 (5.7) 0.22
Reduced activity 10.7 (4.6) 12.2 (3.6) 10.2 (5.4) 10.8 (3.8) 0.67
Reduced motivation 9.2 (4.2) 11.7 (4.0) 9.2 (4.4) 10.4 (3.9) 0.79
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qol and sHBG
A higher SHBG, a marker of hepatic TH status, corresponded with a 
better QOL in 9 out of the 15 subscales (Table 5). An improvement in 
QOL was seen in physical functioning, role limitations due to emotional 
problems, vitality, pain and general health, according to the SF-36 
questionnaire. The HADS revealed an improvement in depression scores 
with higher SHBG levels, and the MFI-20 showed a reduction in physical 
fatigue, in reduced activity and in reduced motivation. SHBG was not 
related to FT4 or T3 levels.
Table 3 (continued)
FT4 < 17.5 17.5 < FT4 < 20.2 20.2 < FT4 < 21.4 FT4 > 21.4 p-value 
for trend
 
n=21 n=24 n=22 n=23
mean (sD) mean (sD) mean (sD) mean (sD)
sF-36 questionnaire
Physical functioning 61 (19) 64 (18) 68 (22) 64 (17) 0.35
Social functioning 70 (24) 71 (28) 74 (23) 63 (28) 0.47
Role-physical 54 (43) 57 (41) 73 (42) 60 (40) 0.38
Role-emotional 81 (37) 68 (42) 89 (24) 70 (43) 0.77
Emotional wellbeing 71 (20) 67 (20) 70 (16) 66 (18) 0.50
Vitality 52 (22) 52 (19) 53 (21) 47 (25) 0.54
Pain 78 (27) 77 (24) 75 (26) 68 (29) 0.22
General health 57 (23) 49 (18) 64 (21) 53 (24) 0.80
HADs
Depression 4.9 (4.3) 6.1 (3.7) 4.1 (2.6) 6.2 (4.5) 0.66
Anxiety 5.7 (3.9) 7.4 (4.8) 6.1 (3.9) 6.9 (4.3) 0.66
Total 10.4 (7.2) 13.5 (8.0) 10.1 (5.7) 13.1 (8.4) 0.55
mFI-20
General fatigue 12.0 (4.6) 12.1 (4.8) 12.1 (5.5) 13.7 (5.6) 0.31
Physical fatigue 12.2 (4.8) 12.5 (4.6) 11.7 (5.4) 13.7 (5) 0.51
Mental fatigue 10.0 (5.1) 10.0 (5.3) 10.5 (5.5) 10.5 (4.9) 0.77
Reduced activity 11.2 (5.1) 10.2 (4.3) 10.4 (4.2) 12.0 (4.1) 0.59
Reduced motivation 10.7 (4.4) 9.6 (3.9) 9.3 (3.8) 11.2 (4.7) 0.72
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An increase in SHBG corresponded with a decrease in BMI. A ‘low’, 
‘normal’ and ‘high’ SHBG corresponded with a BMI of 31.0 kg/m², 
30.1 kg/m² and 26.3 kg/m² respectively (p<0.001). When corrected 
for BMI the correlation between SHBG and QOL disappeared in the 
above mentioned QOL scales, except for SF-36 role limitations due to 
emotional problems and MFI-20 reduced motivation scale.
Table 4. qol at baseline in normal weight, overweight and obese pa-
tients treated for hypothyroidism.
Normal weight 
(n=21)
overweight 
(n=31)
obese
(n=38)
BmI < 25 25 <BmI> 30 BmI> 30
p-value 
for trend
mean (sD) mean (sD) mean (sD)
sF-36 questionnaire
Physical functioning 77 (13) 61 (19) 60 (16) 0.001
Social functioning 76 (27) 72 (23) 64 (26) 0.10
Role-physical 86 (31) 60 (39) 49 (43) 0.001
Role-emotional 85 (30) 77 (35) 72 (44) 0.22
Emotional wellbeing 69 (18) 70 (13) 67 (22) 0.68
Vitality 62 (19) 48 (24) 47 (20) 0.01
Pain 90 (20) 69 (26) 71 (27) 0.007
General health 68 (20) 55 (21) 50 (22) 0.003
HADs
Depression 3.8 (3.2) 5.2 (3.0) 6.3 (4.6) 0.02
Anxiety 6.3 (4.2) 6.7 (4.0) 6.5 (4.5) 0.83
Total 10.0 (7.0) 11.9 (6.4) 12.7 (8.4) 0.21
mFI-20
General fatigue 10.7 (4.9) 12.9 (5.3) 13.2 (4.9) 0.08
Physical fatigue 9.4 (4.9) 12.5 (4.9) 14.0 (4.3) 0.001
Mental fatigue 7.7 (4.0) 11.0 (4.5) 11.0 (5.7) 0.02
Reduced activity 8.0 (3.4) 11.2 (5.1) 12.2 (3.7) 0.001
Reduced motivation 8.0 (3.8) 10.6 (4.3) 11.0 (4.1) 0.01
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qol and autoimmunity
In 61 patients (68%), TPO antibodies were found, and 10 patients 
(11%) had TSHR antibodies. Twelve patients had PC antibodies (positive 
by both immunofluorescence and ELISA) and none of the patients had 
tTG antibodies. No relationship was found between QOL and any of these 
antibodies.
Table 5. sHBG at baseline in tertiles related to qol parameters
SHBG was divided in tertiles in the different populations (men, women<50 years, 
women>50 years). These tertiles were categorized as ‘low’, ‘normal’ and ‘high’ SHBG 
respectively. The tertiles of SHBG were related to QOL questionnaires in treated 
hypothyroid patients.
low sHBG 
(n=30)
Normal sHBG 
(n=30)
High sHBG 
(n=30)
p-value for 
trend
mean (sD) mean (sD) mean (sD)
sF-36
Physical functioning 58 (22) 62 (15) 71 (18) 0.02
Social functioning 68 (22) 60 (28) 78 (23) 0.11
Role-physical 58 (44) 49 (40) 73 (37) 0.16
Role-emotional 64 (44) 69 (42) 93 (19) 0.004
Emotional wellbeing 68 (19) 63 (21) 73 (16) 0.29
Vitality 45 (24) 45 (17) 60 (21) 0.008
Pain 67 (29) 69 (26) 87 (19) 0.004
General health 53 (22) 47 (19) 66 (22) 0.02
HADs
Depression 5.9 (4.3) 6.3 (3.8) 3.9 (3.3) 0.047
Anxiety 7.1 (4.4) 7.4 (4.4) 5.5 (4.2) 0.14
Total 13.1 (8.0) 13.6 (7.3) 9.4 (6.9) 0.06
mFI-20
General fatigue 13.0 (4.7) 13.7 (5.0) 11.3 (5.5) 0.21
Physical fatigue 13.3 (4.8) 14.1 (4.0) 10.7 (5.4) 0.04
Mental fatigue 10.1 (4.6) 11.9 (5.3) 9.3 (5.4) 0.55
Reduced activity 12.2 (4.5) 11.5 (3.6) 9.3 (4.6) 0.01
Reduced motivation 10.7 (4.3) 11.8 (4.1) 8.3 (3.5) 0.03
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qol compared to external controls
QOL in our study population was compared to QOL in healthy controls 
(Leiden controls, n=440) by SF-36, HADS and MFI-20 questionnaires 
(Table 2). The Leiden control group had a similar sex distribution, 
but was 3 years older than our patient group (p=0.04). SF-36 scores 
in hypothyroid patients were markedly lower than in controls in all 8 
subscales, indicating a worse general QOL. Scores on the HADS and 
MFI-20 questionnaires were higher compared to the reference values, 
indicating more depression and anxiety, and fatigue respectively.
A comparison of QOL scores in hypothyroid patients with age-adjusted 
reference values from previous studies, confirmed the reduced QOL in 
the study population on all the measured subscales (Table 2).
DIscussIoN
In this study, we found that in treated hypothyroid patients, QOL was 
not related to the serum levels of TSH, FT4 or T3. This reinforces results 
from other studies, in which no correlation between QOL and thyroid 
parameters could be found. For example, a study on the starting dose 
of LT4 in newly diagnosed hypothyroidism, found a faster normalization 
of thyroid parameters with a high starting dose of LT4 compared with 
an incremental dose regimen, but did not find a faster improvement of 
QOL (30). Two studies on the influence of small changes in LT4 doses, 
and thus TH levels, could not find changes in well-being, hypothyroid 
symptoms, or QOL (15, 31). Our findings could have consequences for 
clinical practice as more than often LT4 dosages are adjusted based 
on the suggested relationship of patient complaints about QOL and TH 
levels just within or outside the normal reference range.
Interestingly, a decreased QOL was related to increasing body weight 
and BMI. Overweight is probably an overlooked aspect in patients with 
hypothyroidism, and could be a large contributor to the reduced QOL. 
In a study on reduced QOL in treated hypothyroid patients, putting on 
weight was significantly more often indicated as a problem by patients 
than by healthy controls (9). Even after therapy is started and the 
excess body water that is associated with myxedema in hypothyroidism 
is lost (32), the weight often remains a problem. Several studies have 
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indeed demonstrated that body weight of patients with primary or 
iatrogenic hypothyroidism increases over the years (33-35). The greater 
weight gain described in the studied subjects compared to age- and 
gender-matched controls, is not due to inadequately normalized TSH 
values (9, 35). Possible causes of weight gain in hypothyroid patients 
may include a failure of LT4 to serve as a full replacement for THs. 
Although FT4 and T3 levels are adequately normalized by LT4 mono-
therapy (36), it is difficult to mimic normal hormone secretion by 
hormonal substitution therapy in hypothyroid patients (37). In a trial 
comparing combined T4/T3 treatment with LT4 monotherapy, there was 
a preference of patients for combination therapy if they lost weight (11). 
A similar patient preference for desiccated thyroid hormone over LT4 
was also connected to weight loss (33).
Obesity in general is known to decrease health-related QOL (38). 
Interestingly, in a Dutch study on QOL in obese and non-obese subjects, 
QOL in obese women was decreased on the same subscales as in our 
population (28). Besides the impact on QOL, obesity is also related 
to health problems such as hypertension, diabetes, cardiovascular 
disease and malignancy (39). Once people have gained weight, most 
interventions directed at weight loss are unsuccessful. It is therefore 
of the utmost importance to prevent weight gain by counselling 
patients and encouraging them to engage in weight loss programs. 
The experience of endocrinologists shows, however, that it is difficult 
to prevent and/or treat weight gain in hypothyroid patients. Further 
investigation is warranted on the cause of weight gain in (treated) 
hypothyroidism, which will hopefully improve treatment of hypothyroid 
patients in the future.
SHBG is known to be a marker of hepatic TH state (17). In our study 
a higher SHBG corresponded with a better QOL on various subscales. 
However, this relationship of SHBG with QOL disappeared in most 
of the subscales after correction for BMI. The level of SHBG varies 
with nutritional status (and thus BMI), age and sex hormones which 
interferes with its use as a sensitive parameter of TH action (40). As 
the majority of hypothyroid patients are female (with fluctuations in 
estrogen levels during life), SHBG is not a suitable marker of TH status. 
In fact, TSH itself is an indicator of tissue TH levels because of the 
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feedback of TH on the hypothalamus-pituitary-thyroid axis. However, as 
mentioned before, TSH did not show a correlation with QOL.
A relationship between QOL and thyroid auto-antibodies, or antibodies 
associated with other auto-immune disorders was not found in our 
study population. Recently, some investigators found a relation between 
thyroid auto-antibodies and mood and depression in subjects with 
a normal thyroid function (19, 20). However, this is not confirmed 
by others (41), which is in line with our results. Perhaps the study 
population needs to be larger do draw definite conclusions on this 
matter. We found a much higher percentage of patients with PC 
antibodies than previously described in a population of patients with 
auto-immune hypothyroidism (13% vs 4.5%) (42). We, however, 
measured PC antibodies, irrespective of symptoms or anaemia, and not 
only in patients with self-reported pernicious anaemia, which is of course 
a smaller proportion of subjects.
In our study population, QOL was decreased compared to the general 
population (26). These findings confirm the reduced QOL found in 
previous studies of treated hypothyroid patients (9, 11). Comparing 
patients with chronic illnesses, QOL in hypothyroid patients is worse 
than in patients with diabetes mellitus (43), but better than in patients 
with fibromyalgia (44). It should be mentioned that QOL in our 
outpatient study population could be worse than QOL in hypothyroid 
patients in general, because of a referral bias of patients with more 
complaints towards an outpatient clinic. However, it is the experience 
of many clinicians, including general pratitioners, that QOL related 
problems tend to persist in treated hypothyroid patients.
In conclusion, in a large group of treated hypothyroid patients, we found 
a decreased QOL that was related to an increased body weight and 
BMI. QOL was not dependent on serum thyroid parameters or auto-
antibodies. These findings are important, as an increase in body weight 
is a frequent finding in treated hypothyroid patients, and should have 
our attention in the treatment of hypothyroidism and in future research.
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supplemental Figure 1.
Correlation between a) BMI tertiles and SF36 (RAND) physical functioning and b) 
BMI and MFI20 physical fatigue. BMI (body mass index) in kg/m2.
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supplemental Table 1 BmI at baseline (in tertiles) related to qol unadjust-
ed vs adjusted for age, sex and TsH (linear regression analysis)
coefficient
(unadjusted) P
coefficient
(adjusted for age, sex, TsH) P
sF-36 questionnaire   
Physical functioning -7.66 0.001 -8.09 0.001
Social functioning -6.04 0.08 -6.06 0.08
Role-physical -17.6 0.002 -18.1 0.001
Role-emotional -6.33 0.22 -7.32 0.16
Emotional wellbeing -1.32 0.6 -1.49 0.55
Vitality -6.64 0.02 -6.65 0.02
Pain -8.3 0.02 -8.68 0.02
General health -8.67 0.004 -8.97 0.003
HADs
Depression 1.25 0.02 1.36 0.01
Anxiety 0.08 0.89 0.17 0.76
Total 1.25 0.22 1.46 0.15
mFI-20
General fatigue 1.12 0.1 1.06 0.13
Physical fatigue 2.23 0.001 2.24 0.001
Mental fatigue 1.43 0.04 1.36 0.05
Reduced activity 1.93 0.001 2.04 0.001
Reduced motivation 1.35 0.02 1.4 0.02
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ABsTrAcT
Uptake of thyroid hormone (TH) by the small bowel is important for the 
enterohepatic cycle of TH and for absorption of TH in patients treated 
for hypothyroidism. TH uptake takes place in the small intestine, 
but the mechanism of uptake remains to be elucidated. Therefore, 
we characterized intestinal TH transport, using the human colorectal 
adenocarcinoma cell line Caco2 as a model.
T4 uptake by Caco2 was Na+ independent, but highly dependent on pH. 
T4 uptake was markedly higher at pH 5.3 than at pH 7.3. At acidic pH, 
T4 uptake was inhibited by leucine and 2-aminobicyclo-(2,2,1)-heptane-
2-carboxylic acid (BCH), prototypic ligands for the L-type amino acid 
transporters, suggesting that T4 is transported in Caco2 cells by an 
L-type amino acid transporter at low pH. LAT1-transfected COS1-cells 
showed the same characteristics of T4 uptake as Caco2 cells and 
RT-qPCR analysis showed abundant mRNA expression of LAT1 in our cell 
line.
T3 uptake by Caco2 cells was both Na+ and pH independent. T3 uptake 
was inhibited by tryptophan and verapamil but not by leucine and 
BCH. This suggests the involvement of a T-type amino acid transporter, 
most likely MCT10. RT-qPCR demonstrated abundant MCT10 mRNA 
expression in our Caco2 cells. Remarkably, the addition of BSP, which is 
a prototypic ligand for organic anion transporting polypeptides as well as 
for multidrug resistance-related efflux transporters, resulted in a marked 
increase in uptake of T3 and in particular T4.
Our data provide evidence that amino acid transporters are important for 
uptake of T4 and T3 by Caco2 cells. T3 uptake appears to be mediated 
largely by MCT10, and T4 uptake by LAT1, in particular at low pH.
89TH transport in intestinal cell model
INTroDucTIoN
In euthyroid subjects, thyroid hormone (TH) transport across the 
intestinal mucosa is an important step in the enterohepatic cycle of 
the hormone. Also, oral replacement therapy of hypothyroid patients 
requires the intestinal absorption of L-thyroxine. Therefore, uptake 
of T3 and T4 by the intestinal wall is clearly important in maintaining 
stable TH levels. Previous studies have shown that the absorption of 
oral L-thyroxine takes place in the small bowel but the mechanisms of 
translocation across the mucosa are unclear (1, 2). Absorption ranges 
from 60% to 80% (3, 4) and is influenced by several factors, including 
dietary habits (5-7), interference by other drugs (8-12) and intestinal 
disorders (13, 14). Earlier studies have shown that the characteristics 
of TH uptake differs between different cell types, with regard to ligand 
specificity, Na+ dependence and interactions with a variety of compounds 
(15). Several TH transporters have been identified in recent years, 
including different organic anion transporting polypeptides (OATPs) (16), 
Na+/taurocholate-cotransporting polypeptide (NTCP) (17), fatty acid 
translocase (FAT or CD36) (18), L-type amino acid transporters LAT1 
and LAT2 (19), and monocarboxylate transporter 8 (MCT8) and MCT10 
(20). Multidrug resistance-associated proteins can function as an efflux 
transporter of TH (21).
The human colorectal adenocarcinoma cell line Caco2 is morphologically 
and functionally similar to human small intestinal epithelial cells making 
it a useful model for intestinal absorption of various compounds (22, 
23). Upon continued culture for 2-3 weeks after reaching confluence, 
Caco2 cells differentiate spontaneously into enterocyte-like cells with 
increased expression of certain transporters and enzymes (22).
The aim of the present study was to characterize the transport of T4 and 
T3 in Caco2 cells, and thereby identify candidate transporters for TH 
uptake and efflux in the intestinal wall.
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mATerIAls AND meTHoDs
materials
[125I]T3 and [125I]T4 were prepared as previously described (24). 
Nonradioactive iodothyronines were obtained from Henning (Berlin, 
Germany). Bromosulphthalein (BSP), 2-aminobicyclo-(2,2,1)-heptane-
2-carboxylic acid (BCH), verapamil (VER), cyclosporin A (CSA), and 
the amino acids tryptophan (Trp), leucine (Leu), tyrosine (Tyr) and 
phenylalanine (Phe) were purchased from Sigma Aldrich (Zwijndrecht, 
The Netherlands [NL]).
To obtain FLAG-LAT1-2.pcDNA3, the full-length cDNAs for human LAT1-2 
were obtained from Thermo Fisher Scientific (Landsmeer, NL) and 
subcloned into the expression vector pcDNA3 using oligonucleotides 
(Integrated DNA Technologies, Leuven, Belgium) containing a FLAG tag 
and suitable restriction sites. All constructs were checked by sequencing 
(BaseClear, Leiden, NL). Mouse CD98.pcDNA3 was kindly provided by 
Dr. Gerd Krause (Leibniz-Institut für Molekulare Pharmakologie, Berlin, 
Germany).
cell culture
Caco2 cells were obtained from the European Collection of Cell Cultures 
ECACC (Salisbury, UK). The cells were used between passages 42 
and 60, and cultured as monolayers in 6-well culture dishes (Corning, 
Schiphol, NL) in DMEM/F12 medium supplemented with 9% heat-
inactivated fetal bovine serum and 100 nM Na2SeO3 at 37 °C in a 
humidified atmosphere of 5% CO2-95% air. The cells were seeded 
at 300,000 cells/well and grown until confluence or cultured for an 
additional 14 days, in which case the culture medium was replaced 
every other day.
COS1 cells were cultured at 37 °C and 5% CO2 in 75 cm2 flasks with 
DMEM/F12 (Life Technologies, Bleiswijk, NL) supplemented with 
9% heat-inactivated fetal bovine serum (Sigma Aldrich), penicillin-
streptomycin, and 100 nM Na2SeO3. At confluence, cultured cells were 
split and seeded in 24-well dishes. At 70% confluence, cells were 
transiently transfected using X-treme Gene 9 Transfection Reagent 
(Roche, Almere, NL). The cells were transfected with 250 ng pcDNA3 
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(empty vector, EV) or with 50 ng FLAG-LAT1-2.pcDNA3 plus 50 ng CD98.
pcDNA3 supplemented with 150 ng pcDNA3.
TH transport experiments
Caco2 cells were washed with incubation medium (142.9 mM NaCl, 
4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1.8 mM CaCl2, 20 mM 
HEPES, 0.1% glucose and 0.1% BSA, pH 7.3) or phosphate buffered 
saline (PBS) with 0.1% glucose and 0.1% BSA. Uptake of iodothyronines 
was tested by incubation of the cells for 5-180 min at 37 °C with 1 
nM (2x105 cpm) [125I]T3 or [125I]T4 in 1.5 ml incubation medium. After 
incubation, cells were washed with medium and lysed with 1 ml 0.1 
M NaOH. Radioactivity in the lysate was measured in a γ-counter. The 
uptake experiments were performed in the absence or presence of 
varying concentrations of nonradioactive iodothyronines, 1 mM BCH, 
Leu, Phe, Tyr or Trp, or 0.1 mM BSP, VER or CSA.
To evaluate the Na+ dependence of T3 or T4 uptake, Na+ in the incubation 
medium was replaced by an equimolar amount of choline. To evaluate 
the pH dependence of T3 or T4 uptake, the pH of the incubation medium 
was adjusted from 7.3 to 6.3 or 5.3.
uptake by lAT1 and lAT2
Two days after transfection, COS1 cells were washed with assay buffer 
(D-PBS + Ca2+/Mg2+ + 0.1% glucose) and incubated for 30 minutes 
at 37 °C with 10 nM (50,000 cpm) [125I]T4 or [125I]T3 in 0.5 ml assay 
buffer with or without 0.1% BSA and with or without 1 mM BCH. After 
incubation, cells were washed with assay buffer, lysed with 0.1 M NaOH, 
and counted.
rT-qPcr of TH transporters in caco2 cells
Caco2 cells were plated in 12-well plates at 2x105 cells/well and cultured 
for 4 or 21 days. Total RNA was isolated using the High Pure RNA Isolation 
kit (Roche), according to the manufacturer’s instructions. One µg total 
RNA was reversely transcribed using the Transcriptor High Fidelity cDNA 
Synthesis kit (Roche). Quantitative real-time PCR was performed using 
the qPCR Core kit for SYBR® Green I No dUTP (Eurogentec, Maastricht, 
NL). Cyclophilin A (peptidylprolyl isomerase A, PPIA) was used as 
housekeeping gene for normalization of mRNA amplification. The primers 
used for qPCR are listed in Supplemental Table 1.
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statistical analysis
All results are the means ± SEM of at least duplicate determinations 
from representative experiments. Statistical significance was determined 
using the Student’s t test for unpaired observations.
resulTs
General transport characteristics
T4 and T3 uptake by Caco2 cells was measured at different incubation 
times. Uptake of both T4 and T3 increased over time, with T3 uptake 
being 3-4 fold higher than T4 uptake using medium with 0.1% BSA at 
pH 7.3 (Figure 1).
T4 transport was highly influenced by the pH of the medium, with a 3-4 
fold higher uptake at pH 5.3 than at pH 7.3 (Figures 1-3), whereas T3 
uptake was not significantly affected by the pH value. There was a small 
increase in T4 uptake at pH 5.3 by cells cultured for 21 days compared 
with cells cultured for 4 days. T3 uptake was slightly reduced comparing 
cells cultured for 21 vs. 4 days (Figure 2).
To exclude the possibility that the increased T4 uptake at a lower pH 
was caused by a decreased T4 binding to BSA, the experiments were 
Figure 1.
Time course of uptake of 1 nM [125I]T3 and [125I]T4 by Caco2 cells at different pH 
values (5.3, 6.3, 7.3) in phosphate buffered saline with 0.1% glucose and 0.1% BSA 
Mean ± SD of duplicate measurements.
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also performed in the absence of BSA, which showed that the uptake 
of T4 and T3 was markedly higher compared with medium containing 
0.1% BSA. The influence of pH on T4 uptake, however, was unaffected 
(Figure 4). To investigate the Na+ dependence of T4 and T3 transport, 
we performed experiments using standard incubation medium or 
medium where Na+ was replaced with equimolar amounts of choline. 
The results indicated that both T4 and T3 transport are Na+ independent 
(Figure 3).
Figure 2. Uptake of T3 and T4 in different pHs in Caco-2 cells after 4 days and 
21 days culture. N=2. ***p<0.001; *p<0.05 t test
Figure 3. Na+ and pH dependence of 1 nM [125I]T4 and [125I]T3 uptake by 
Caco2 cells during incubation for 60 min in incubation medium (142.9 mM 
NaCl or choline choride, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 1.8 mM 
CaCl2, 20 mM HEPES, 0.1% BSA and 0.1% glucose, pH 5.3 or 7.3). Mean ± 
SEM, n=2.
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Kinetic studies with increasing concentrations of substrate showed 
saturation of T4 transport at pH 5.3, with an apparent Km value of about 
10 µM, but no saturation at pH 6.3 and 7.3 (Figure 5). Saturation of T3 
transport was independent of the pH of the incubation medium, with an 
apparent Michaelis constant (Km) value between 1-10 µM.
Figure 4. Effect of BSA (0, 0.1 or 1%) and pH (5.3, 6.3 or 7.3) on the uptake 
of 1 nM [125I]T3 and [125I]T4 uptake by Caco2 cells during incubation for 60 
min in PBS with 0.1% glucose. Mean ± SEM, n=3.
Figure 5. Effects of increasing substrate concentrations (0.1, 1, 10 µM) on 
the uptake of [125I]T3 and [125I]T4 during incubation for 60 min in PBS with 
0.1% glucose and 0.1% BSA (pH 5.3, 6.3, 7.3). Mean ± SEM, n=5.
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Inhibition of T4 and T3 transport by competitive 
transporter substrates
The characteristics of T4 and T3 transport in Caco2 cells were further 
studied by testing the effects of prototypic ligands for L- and T-type 
amino acid transporters, OATPs and multidrug-resistance (MDR) related 
efflux transporters.
At pH 7.3, uptake of T4 was inhibited by 24% with the T-type amino 
acid transporter substrate Trp but not by the L-amino acid transporter 
substrates Leu and BCH, all tested at 1 mM (Figure 6). However, at 
lower pH, T4 uptake became progressively inhibited by Leu and BCH up 
to 37% at pH 5.3. T4 uptake was also inhibited by 33% at pH 7.3 and 
by 27% at pH 6.3 by 0.1 mM VER, a calcium channel blocker which also 
inhibits P-glycoprotein (25), but it was not inhibited by 0.1 mM CSA, 
another P-glycoprotein inhibitor (25), irrespective of pH (Figure 7).
Figure 6: Effects of 1 mM amino acid transporter substrates on the uptake 
of 1 nM [125I]T3 and [125I]T4 during incubation in PBS with 0.1% glucose and 
0.1% BSA, pH 6.3 or 7.3. Ctrl, control; Leu, leucine; Trp, tryptophan; BCH, 
2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid. Mean ± SEM, n=3. * 
P<0.05 vs. Ctrl. ND, not determined. Numbers above the Ctrl bar represent 
%T3 uptake in the absence of competitors.
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T3 uptake was not inhibited by 1 mM of the L-type amino acid transporter 
specific compounds BCH and Leu (Figure 6). However, T3 uptake was inhibited 
by substrates for T-type amino acid transporters (26), i.e. by 47% with 1 mM 
Trp (Figure 6), by 15% with 1 mM Phe and by 18% with 1 mM Tyr (not shown). 
Uptake of T3 was also inhibited by 62% with 0.1 mM VER and by 29% with 0.1 
mM CSA (Figure 7).
BSP is a prototypic substrate for OATPs and MDR related efflux transporters 
(27). Remarkably, addition of 0.1 mM BSP resulted in a marked increase in T4 
uptake by 195% at pH 7.3 and by 78% at pH 6.3, and an increase in T3 uptake 
by 43.6% (pH 7.3). A smaller BSP-induced increase in T4 uptake was also 
observed in the absence of BSA (38% at pH 7.3; not shown).
The Na-independent uptake of T4 by Caco2 cells and its inhibition by BCH 
and Leu suggested the involvement of L-type amino acid transporter(s) LAT1 
or LAT2. LAT1 (SLC7A5) and LAT2 (SLC7A8) are the light chains which form 
functional heterodimeric transporters with the common heavy chain CD98 
(SLC3A2) (28)) Therefore, we tested T4 uptake in COS1 cells co-transfected 
with LAT1 or LAT2 and CD98. T4 transport was not increased in cells 
transfected with LAT2, compared with cells transfected with empty vector (29). 
LAT1-transfected cells, however, showed pH-dependent uptake of T4, which 
was inhibited by BCH (Figure 8), in agreement with the Caco2 cell studies. In 
the absence of BSA, T4 uptake increased, but pH dependence remained intact. 
LAT1 also showed significant pH-dependent transport of T3 (Figure 8).
Figure 7: Effects of 1 mM OATP and MDR transporter substrates on the uptake of 1 
nM [125I]T3 and [125I]T4 during incubation in PBS with 0.1% glucose and 0.1% BSA, 
pH 6.3 or 7.3. Ctrl, control; BSP, bromosulphthalein, VER, verapamil, CSA, cyclospo-
rine A. Mean ± SEM, n=3. * P<0.05 vs. Ctrl. Numbers above the Ctrl bar represent 
%T3 uptake in the absence of competitors.
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RT-qPCR analysis demonstrated marked expression of LAT1, LAT2 and MCT10 
in Caco2 cells after 4 and 21 days of culture. Expression of LAT1 was 42% 
lower at 21 days than at 4 days of culture (Figure 9), LAT2 and MCT10 
expression increased by respectively 21% and 16% at 21 days.
Figure 8: Effects of pH and BCH (1 mM) on uptake of [125I]T4 or [125I]T3 (1 
nM) by COS1 cells transfected with LAT1 after incubation for 30 min in PBS 
with 0.1% glucose and without or with 0.1% BSA. Mean ± SEM (n=3).
Figure 9: Expression of Thyroid hormone transporters LAT1, LAT2 and MCT10 
in Caco-2 cells after 4 days and 21 days culture. MCT8 was not expressed. 
N=4. **p<0.01 t test
 98
DIscussIoN
We used Caco2 cells as a model to explore TH transport characteristics 
in intestinal cells. Both T4 and T3 uptake by Caco2 cells increase with 
time, are saturable and Na+-independent, implying the involvement 
of Na+-independent transporters in these processes. Furthermore, T4 
uptake is highly pH dependent, being markedly higher at pH 5.3 than at 
neutral pH. This is in contrast with the pH independence of T3 uptake 
and may be explained by the different effects of pH on the T3 and T4 
molecules. The pK value of the phenolic hydroxyl group of T4 is ~6.5 
and that of T3 ~8.5. This implies that this part of the T4 molecule is 
largely neutral at pH 5.3, whereas it largely exists as the phenolate 
anion at pH 7.3. In contrast, the phenolic hydroxyl group of T3 does not 
dissociate if pH is increased from 5.3 to 7.3, and thus remains largely 
neutral. However, it could also mean that different transporters are 
involved in T4 and T3 uptake.
Inhibition studies showed that T4 uptake at acidic pH was inhibited by 
Leu and BCH. The latter is a prototypic substrate for L-type amino acid 
transporters which transport large aliphatic and aromatic amino acids 
such as Leu, Trp, Tyr and Phe. There are at least 4 L-type amino acid 
transporters, i.e. LAT1 (SLC7A5), LAT2 (SLC7A8), LAT3 (SLC43A1) 
and LAT4 (SLC43A2) (30, 31). Recents studies from our lab indicate 
that LAT1 transports both T4 and T3, whereas LAT2 only transports T3 
(19). LAT1-transfected COS cells showed the same characteristics of T4 
uptake as Caco2 cells, i.e. increased uptake at lower pH and inhibition 
by BCH.
Independent of pH, T4 and T3 uptake by Caco2 cells is inhibited by VER 
and Trp. VER was tested as an inhibitor of P-glycoprotein to investigate 
the possible role of this efflux transporter on cellular accumulation of T4 
and T3 in Caco2 cells. We therefore expected possible stimulation of net 
T4 and T3 uptake, but instead we observed significant inhibition of T4 
and T3 uptake by VER. We have recently demonstrated dose-dependent 
inhibition of T4 and T3 uptake by MCT8 as well as MCT10 by VER 
(Sanne Noort, Theo J. Visser, unpublished work). Both MCT8 and MCT10 
facilitate T3 and T4 transport in a Na+-independent and pH-independent 
manner, with MCT10 clearly prefering T3 over T4 as the substrate. The 
marked inhibition of T4 and T3 uptake by VER and aromatic amino acids, 
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but not by Leu or BCH at neutral pH, suggests the involvement of MCT10 
in this process.
BSP was tested as a prototypic substrate for OATPs, and a decrease (not 
an increase) in TH uptake in the presence of BSP was expected, if OATPs 
were to be involved in TH transport. The same increased uptake of TH in 
the presence of BSP was seen in HepG2, JEG3, COS1 and SHSY5Y cells 
(data not shown). Possible explanations of the increased TH uptake with 
BSP include 1) inhibition of cellular TH efflux by BSP, b) inhibition of TH 
binding to BSA by BSP, and c) the existence of an exchange mechanism 
where intracellular BSP drives the uptake of extracellular TH.
It is unclear if T4 and T3 transport in Caco2 cells is representative of 
TH transport in human enterocytes. LAT1 and LAT2 are known to be 
expressed in Caco2 cells (32), which was confirmed in our study. LAT1 
mRNA has not been detected in the human intestine (33, 34), but a 
recently published map of the human tissue proteome reports a high 
expression of the LAT1 protein in the small intestine (35). In murine 
small intestinal cells LAT1 is located at the basolateral mebrane (36). 
To appreciate the function of LAT1 in the intestinal absorption of T4, 
it would be important to know if it is localized in the apical (luminal) 
or basolateral membrane. Although we demonstrated MCT10 mRNA 
expression in Caco2 cells, the MCT10 protein appears to be located 
in the basolateral membrane of human enterocytes (32, 37). This 
transporter, therefore, cannot be involved in the uptake of TH from the 
intestinal lumen but only from the blood. However, MCT10 appears to 
facilitate both cellular uptake and efflux of substrates. Therefore, it may 
also mediate the release of iodothyronines from the enterocytes into the 
blood.
In the present study we investigated TH transport in Caco2 cells as a 
model for TH transport in the human intestine. As absorption of T4 from 
the intestinal tract is a prequisite in the treatment of hypothyroidism, we 
chose this human cell line as a model instead of using cells from animal 
models. It is difficult to assess to which extent transport by Caco2 cells 
indeed represents transport in human enterocytes in vivo. Therefore, 
extrapolation of findings in Caco2 cells to human physiology may have 
limitations. However, Caco2 cells are commonly used to study transport 
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of various drugs in the small intestine (22). Therefore, it is generally 
accepted that these cells may serve as a model for transport processes 
in the human intestine.
In conclusion, we have provided evidence that there is transport of T3 
and T4 in Caco2 cells and have described the transport characteristics. 
These characteristics are needed to understand the mechanisms of 
transport of TH by enterocytes. At neutral pH, MCT10 seems important 
in the transport of T3, and to a lesser extent T4. At acidic pH LAT1 
seems to be important for T4 transport. Further studies are required 
to identify the transporters responsible for TH absorption in the human 
intestine.
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supplemental Table 1. Primers sequence of the human THT
1 MCT8_Fw CCTCTACTCCATGCTGCTA
2 MCT8_Rv CGGTTGCTGTGATTCGG
3 MCT10_Fw TGCTCTTCGTGTCCATGCTG
4 MCT10_Rv GAGAGAGAACCTACCCATGC
5 LAT1_Fw GAAGGGTGATGTGTCCAATCT
6 LAT1_Rv GCAAAGAGGCCGCTGTATAA
7 LAT2_Fw CATCGTAGGGAACATCATCGG
8 LAT2_Rv GAGTTCAGCATAGCAGAGGG
9 PPIA_Fw TTTCCAGGCCCCTTACCTCG
10 PPIA_Rv CATGGTCAACCCTACCGTGT
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ABsTrAcT
An adequate absorption of levothyroxine (LT4) by the intestine is an 
essential part of the treatment of hypothyroid patients. In the last 
decades research has provided more information on the location and 
mechanism of LT4 absorption in the gut. In this review we describe 
the available data on LT4 absorption and factors interfering with this 
absorption. To comprehend how a hypothyroid patient can best be 
treated with LT4, the mechanism of T4 uptake by the enterocyte and 
the entero-hepatic cycle of T4 and T3 are first described. In vitro 
experiments in Caco2 cells (a colon carcinoma cell line frequently used 
to study absorption in small intestinal cells) show the characteristics 
of the thyroid hormone transporters in the gut, and demonstrate the 
importance of an acidic environment for LT4 uptake. This explains why 
conditions impairing gastric acidity result in decreased absorption of T4. 
Interference of LT4 uptake by gastrointestinal disorders, several drugs 
and food is described next. Because of these interferences the timing 
of LT4 intake is important. Studies show that LT4 should be ingested on 
an empty stomach, where bedtime administration is an alternative to 
morning ingestion. Finally, pseudo-malabsorption (non-compliance) is 
often a diagnostic challenge. A guideline is presented how to carefully 
investigate this clinical problem.
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INTroDucTIoN
The absorption of T4 by the intestinal tract is an essential step in the 
treatment of hypothyroid patients, to adequately treat well-known 
hypothyroid symptoms (1, 2) and reach stable thyroid hormone levels. 
To reach normal T4 and T3 levels, hypothyroid patients are treated 
with synthetic T4 (levothyroxine, LT4), that is converted into T3 
after absorption. Not only in hypothyroid patients but also in healthy 
euthyroid people T4 absorption is important, as it constitutes an 
important step in the entero-hepatic cycle of the hormone. During the 
last decades more information has become available on the location 
and the mechanism of T4 absorption by the intestine, and the factors 
influencing this absorption. We will present an overview of the available 
data of the research in this rapidly expanding field.
seArcH sTrATeGy
Pubmed database was searched for the terms (“Thyroxine”[mesh] 
OR Thyroxine[tiab] OR Thyroxin[tiab] OR “L-Thyroxine”[tiab] 
OR “L Thyroxine”[tiab] OR “Thyroid Hormone”[tiab] OR “Thyroid 
Hormones”[tiab] OR “thyroid treatment”[tiab] OR Levothyroxine[tiab] 
OR “L-T4”[tiab] OR LT4[tiab]). The results were cross-referenced with 
keywords relevant to the subsections. Additional references were 
identified from review articles and original research articles.
INTesTINAl ABsorPTIoN AND eNTero-HePATIc 
cycle
To understand the factors influencing the absorption of synthetic T4 
(LT4) in hypothyroid patients, the mechanism of T4 absorption in the 
small intestine will first be described. Currently, it is known that the 
absorption of oral T4 across the mucosa takes place in the small bowel 
(3, 4). The location of T4 absorption was studied around the time that 
LT4 became commercially available (1970). In 1968 Hays wondered 
why athyreotic people needed 300 μg thyroxine to become euthyroid, 
while the normal thyroid gland secretes only about 80 μg of T4. As she 
suspected incomplete absorption of the oral thyroxine, she studied the 
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absorption of T4 by a double-isotope technique (3). T4 labelled with 
125I was administered orally simultaneously with intravenous T4 labelled 
with 131I. The resulting serum 125I/131I ratio indicated a mean intestinal 
absorption of 71.1 +/- 9.0%. Later studies, including non-isotopic 
studies, confirmed an absorption of 60-80% after oral administration 
(4). T4 absorption occurs within the first 1-3 h of ingestion (5) and is 
localised mainly in the jejunum and the ileum (6). These findings seem 
to be in agreement with the experience of hypothyroid patients, who 
needed higher doses of LT4 after jejuno-ileal bypass surgery or other 
bowel resection. (7-9)
After absorption, T4 is transported to target tissues where it is further 
metabolised  Peripheral thyroid hormone metabolism is mediated mainly 
by the three deiodinases (D1, D2 and D3), that catalyse the inner ring 
and/or outer ring deiodination of the different iodothyronines (10). 
D1 and D2 remove an iodine from the outer ring of the iodothyronine 
molecule, converting the biologically inactive prohormone T4 to the 
bioactive T3.
In addition, alternate pathways of thyroid hormone metabolism exist. 
These include conjugation of the phenolic hydroxyl group, decarboxylation 
and deamination of the alanine side chain and ether-link cleavage 
T4
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Figure 1 Metabolism of T4 by deiodination, sulfation and 
glucuronidation(adapted from thesis W.W. de Herder).
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(minor pathway) (11, 12). Conjugation of T3 and T4 is important in the 
enterohepatic cycle of thyroid hormones (Figure 1). Conjugation with 
sulfate or glucuronic acid increases the water-solubility of compounds, 
facilitating their biliary or urinary excretion. The sulfotransferases play a 
prominent role in the regulation of thyroid hormone metabolism, since 
sulfation of T3 and T4 accelerates their deiodination by D1 to the inactive 
metabolites rT3 and T2 (13). Glucuronidation of iodothyronines by UDP-
glucuronyltransferases primarily occurs in the liver. The glucuronidated 
iodothyronines (T3G and T4G) are excreted in the bile and ultimately 
disposed of with the feces (14, 15). T3G and T4G, however, also serve as 
a thyroid hormone reservoir, as deconjugation back to T3 and T4 occurs 
in the intestinal lumen, catalysed by β-glucuronidases from intestinal 
bacteria (16, 17). Through intestinal absorption of the recovered T3 and 
T4, the hormones re-enter the portal circulation and are again available to 
the liver. Where and how the absorption of the recovered T3 and T4 takes 
place is unclear.
T4 TrANsPorT IN INTesTINAl cells
Around 1990, Hays and DiStefano concluded that T4 uptake is 
equally distributed over the entire intestinal tract and takes place by 
simple diffusion (6, 18). Although the side chain of iodothyronines 
is hydrophilic, it was assumed that the lipophilic aromatic part of 
T3 and T4 could diffuse through the lipid bilayer of the intestinal 
cell membranes. Studies of thyroid hormone uptake in other tissues 
however, show clearly that thyroid hormone traverses the cell membrane 
mainly with the help of transporters, indicating an active process (19).
Thyroid hormone uptake has different characteristics across cell 
types, with regard to ligand specificity, energy (ATP) dependence, 
Na+-dependence and interaction with various compounds (20). 
Several thyroid hormone transporters have become known over 
the years, including Na+/taurocholate cotransporting polypeptide 
(19), fatty acid translocase (21), multidrug resistance-associated 
proteins (22), L-type amino acid transporters (23), and members of 
the organic anion-transporting polypeptide (OATP) family (24) and 
monocarboxylate transporter (MCT) family (25). Some of the known 
thyroid hormone transporters have been localized in the small intestine, 
 112
including OATP1A2 (26), OATP2B1(27), MCT10, LAT1 and LAT2 (28). 
Recently we characterized the transport of T4 and T3 using the human 
colorectal adenocarcinoma cell line Caco2 as a model. (Kelderman-Bolk, 
submitted). This cell line is morphologically and functionally similar 
to human small intestinal epithelial cells making it a useful model for 
intestinal absorption of various compounds (29).
T4 uptake by Caco2 cells turned out to be Na+ independent, but highly 
dependent on pH, T4 uptake being markedly higher at pH 5.3 than 
at pH 7.3. Kinetic studies with increasing concentrations of substrate 
showed saturation of T4 transport at pH 5.3 (with an apparent Km 
value of about 10 µM), which confirms that transporters are involved 
in the transport of T4 over the intestinal wall. The characteristics of T4 
transport in Caco2 cells were further studied by testing the effects of 
prototypic ligands for the known thyroid hormone transporters. At acidic 
pH, T4 uptake is inhibited by prototypic ligands for the L-type amino acid 
transporters (leucine and 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic 
acid (BCH)), suggesting that T4 is transported in Caco2 cells by an 
L-type amino acid transporter (LAT 1 or 2) at low pH. Transporters of the 
OATP family are also known for pH-dependent transport (30), but our 
experiments suggest that OATPs have no role in intestinal uptake of T4, 
or that Caco2 cells are not a good model to identify human intestinal T4 
transporter.
T3 uptake by Caco2 cells is both Na+- and pH independent, and thus 
seems to be mediated by another transporter than T4 uptake. Inhibition 
studies indicate that T3 uptake is mediated largely by a T-type amino 
acid transporter, most likely MCT10. Further studies to clarify the 
exact mechanism of T4 and T3 uptake by intestinal cells should include 
knockdown experiments with siRNA, to test the importance of candidate 
transporters in T4 and T3 uptake.
FAcTors INTerFerING wITH THyroxINe 
ABsorPTIoN
There are several conditions in which the need for LT4 is increased. 
These include pregnancy (31) and the use of drugs that cause 
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hypothyroidism. This review, however, will only focus on conditions 
causing LT4 malabsorption in the gut.
Gastrointestinal disorders
The most apparent disorders where LT4 absorption is impaired, are 
in patients with a resection of part of the bowel or after an intestinal 
bypass. Because part of the gut is not available for T4 absorption, an 
increased dose of LT4 is required in these patients (7-9, 32). Besides 
that, conditions impairing gastric acidity and malabsorptive disorders 
can also affect the bioavailability of T4.
As the studies in Caco2 cells showed, T4 uptake is highly influenced 
by the acidity of the environment. This explains why conditions 
impairing gastric acidity result in decreased absorption of T4 (33, 34). 
In Helicobacter pylori infection of the stomach gastric acid secretion is 
impaired because of bacterial production of urease, which neutralises 
gastric pH. Centanni et al. (33) demonstrated an increased need of T4 
in patients with H. pylori infection and atrophic gastritis. Medications 
that suppress gastric acidity may interfere with T4 absorption as well. 
However, conflicting results have been reported for the effects of proton 
pump inhibitors and the H2-receptorantagonist famotidine (33, 35-39). 
The apparent pH dependence of intestinal T4 absorption in vivo as 
well as of T4 uptake in Caco2 cells in vitro may be explained by the 
involvement of a pH dependent transporter, or by the effect of pH on the 
T4 molecule. The pK value of the phenolic hydroxyl group of T4 is ~6.5, 
which implies that this part of the T4 molecule is largely neutral at lower 
(acidic) pH values, whereas it largely exists as the phenolate anion at pH 
7.3. In contrast, the phenolic hydroxyl group of T3 (pK ~8.5) does not 
dissociate if the pH rises to pH 7.3 and thus remains largely neutral.
In coeliac disease, lactose intolerance and parasitic infections, 
malabsorption of T4 leads to the need for an increased LT4 dose (40). 
Various cases of T4 malabsorption in coeliac disease have been reported 
(32, 40-42). It is hypothetised that partially undigested substances 
interact with LT4, making LT4 less available for absorption (40, 43). 
Patients with coeliac disease also have a different intestinal microbiota 
profile compared to controls (44), which could be another cause of LT4 
malabsorption (45). Following treatment with a gluten-free diet the LT4 
requirements often return back to normal. Coeliac disease and atrophic 
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gastritis occur frequently in patients with autoimmune hypothyroidism 
(46). Therefore, when a patient needs higher LT4 doses than expected, 
screening for coeliac disease and pernicious anemia (atrophic gastritis) 
is warranted. A small cohort study showed an increased need for oral 
LT4 in hypothyroid patients with lactose intolerance (47). In a case 
report T4 malabsorption in a patient with lactose intolerance improved 
with a lactose-free diet and lactose-free LT4 tablets (48). Seppel et al. 
described a case of a parasitic infection by intestinal giardiasis, causing 
T4 malabsorption (49).
Inflammatory bowel disease is mentioned in several review articles as 
a possible cause of T4 malabsorption (32, 43). However, no original 
studies describing this phenomenon are available to our knowledge.
Recently, two studies showed unchanged, or even improved absorption 
of LT4 after sleeve gastrectomy, Roux-en-Y gastric bypass and bilio-
pancreatic diversion (50, 51). The authors conclude that the stomach, 
duodenum and upper jejunum are not important for LT4 absorption. 
This is in conflict with the earlier described results (7-9) . The authors 
speculate that bypassing the biliary secretions (containing glucuronized 
T4), changes in gut microbiota or reduced binding of LT4 to proteins 
normally present in the stomach, could explain the results. A better 
compliance, the weight loss or a diet change after surgery are other 
possible explanations for the presented results.
Food and drinks
Wenzel and Kirchsieper first reported on the impairment of LT4 
absorption by simultaneous food intake (52), which was later confirmed 
by a study of Benvenga et al. (53). The latter study showed that 
maximum T4 absorption occurs between 30 and 60 minutes following 
LT4 ingestion, and that most T4 was absorbed within the first 90 
minutes. When patients took LT4 15 minutes prior to breakfast, a 
delayed time to peak T4 absorption, reduced maximal absorption and 
decreased maximal increment in T4 absorption were seen. The results 
suggested an impairment in the early phase of the absorption. After 
separating breakfast and LT4 intake by at least 60 min thyroid hormone 
levels normalized, which led to the current recommendations to ingest 
LT4 60 min prior to breakfast.
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A fibre-enriched diet also affects the bioavailability of LT4, as suggested 
by higher TSH levels and/or higher LT4 requirements (54). In vitro 
studies with various amounts of wheat bran showed a dose-dependent 
non-specific adsorption of LT4, explaining the reduced T4 bioavailability. 
No interference was found of the fibre supplements calcium 
polycarbophil or psyllium with LT4 absorption (55).
Several case-reports describe persistent hypothyroidism in treated 
patients consuming soy foods (56). The impact of soy on LT4 
requirements appears to result from malabsorption, not from a systemic 
effect on the thyroid. This is concluded from experiments in the 1950’s 
that demonstrated increased fecal excretion and decreased urinary 
clearance of LT4, in patients receiving soy compared to milk formula. 
The mechanism of decreased T4 absorption is unclear; it may be caused 
by sequestration of T4 in the intestine by soy, or interference with T4 
uptake by a thyroid hormone transporter.
Espresso coffee was found to decrease the absorption of LT4 (57). In 
patients on LT4, elevated TSH levels decreased after separating coffee 
intake from LT4. In vitro binding studies indicated that coffee is able to 
sequestrate T4, explaining the reduced bioavailability. The study further 
showed that the intra-gastric pH is not changed by coffee.
To overcome the problems with LT4 absorption in patients drinking 
espresso coffee, a soft gel capsule containing T4 in glycerine has been 
developed that is unaffected by consumption of coffee (58). The authors 
suggest that this capsule might also overcome absorption problems in 
patients with gastrointestinal disorders. A liquid LT4 formulation has 
also been introduced in a few countries. An in vitro study measuring 
T4 by liquid chromatography-tandem mass spectrometry, showed 
that T4 is stable when this liquid LT4 formulation is added to various 
breakfast beverages (59). A clinical study showed no difference in serum 
thyroid parameters when liquid LT4 was consumed with breakfast or 
consumed 30 minutes before breakfast (60). A study in patients with 
impaired LT4 absorption by proton pump inhibitors, showed a correction 
of this malabsorption when patients switched to the oral solution LT4 
in comparison with a LT4 tablet (61). The oral solution might resolve 
malabsorption of LT4 in many of the above described conditions.
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Like coffee, fruit juices are also frequently consumed around breakfast 
time. Grapefruit juice increases the plasma concentrations of several 
drugs that are substrates for CYP3A4 through inhibition of this enzyme 
(62). However, grapefruit juice may decrease the plasma concentrations 
of other drugs, possibly by inhibiting uptake by intestinal transporters, 
in particular OATPs (63). The effect of grapefruit juice on LT4 absorption 
was studied in ten healthy subjects, showing limited effects on the 
pharmacokinetics of LT4: the amount of T4 absorbed was only slightly 
decreased, while tmax was not significantly prolonged (64). Cellular 
uptake of T4 is decreased by orange juice in vitro (unpublished work), 
apparently by binding of T4 to the fibres present in orange juice. To our 
knowledge, the effect of orange juice on the bioavailability of LT4 has 
not been studied in vivo.
Interestingly, a recent report showed that LT4 absorption was 
improved in patients with gastritis when the dose was ingested with 
water containing vitamin C (65). This again stresses the importance 
of an acidic environment for T4 absorption. The reduced acidity in 
gastrointestinal disorders could possibly be overcome by vitamin C 
supplementation.
Drugs
First, the formulation of LT4 itself and the bioequivalence of different 
brands need some attention, as there are concerns among clinicians 
that brand name LT4 and generic LT4 formulations are not clinically 
interchangeable. Since 1997 the quality of manufactured and distributed 
LT4 has improved by monitoring by the Food and Drug Administration 
(FDA). According to current guidelines, tablets should contain 95-105% 
of labelled content (66). Clinicians however have different experiences 
with interchangeability of LT4 formulations, and point out the inability of 
FDA pharmacokinetic testing, using supra-therapeutic doses, to predict 
clinical outcomes with significantly lower doses (67). A joint statement 
of The Endocrine Society and American Thyroid Association therefore 
still recommends that patients should not switch from LT4 brand or 
generic formulation, or should have their TSH retested after switching 
their LT4 preparation (68).
The list of several, often commonly prescribed, drugs that interfere with 
the bioavailability of LT4 has increased over the years (Table 1) (32). 
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For most drugs it is assumed that the reduced bioavailability of LT4 is 
caused by sequestration of T4 in the intestinal lumen or by decreased 
gastric acidity. For some, but not all, drugs the mechanism for the 
reduced bioavailability of LT4 has been studied in vivo and in vitro.
In1969 Northcutt reported on a decreased intestinal absorption of LT4 
with the concomitant use of the bile sequestrant cholestyramine (69). In 
vitro studies showed that 50 mg of cholestyramine bound at least 3000 
µg LT4. The results from this study led to the recommendation to take 
LT4 and cholestyramine 4-6 hours apart. Interestingly, cholestyramine 
has also been studied for the treatment of thyrotoxicosis in Graves’ 
disease (70, 71). The excess of thyroid hormone in the enterohepatic 
circulation in patients with Graves’ disease is successfully reduced by 
cholestyramine. When cholestyramine is added to the treatment with 
propylthiouracil (PTU), this results in a faster normalisation of thyroid 
hormones than treatment with PTU alone (70, 71). Colesevelam 
hydrochloride, a sequestrant with apparently higher affinity for bile 
Table 1 Drugs reducing the absorption of levothyroxine
Drug effect mechanism
Cholestyramine Decreased absorption T4 Irreversible cholestyramine-thyroxine 
complex
Colesevelam Decreased absorption T4 No in vitro study available
Ferrous sulfate Decreased absorption T4 Insoluble ferric-thyroxine complex
Sucralfate Conflicting data about 
possible decreased 
absorption T4?
Sucralfate-thyroxine complex or impaired 
gastric acidity
Aluminium 
hydroxide
Decreased absorption T4 Adsorption or complex forming or impaired 
gastric acidity
Calcium carbonate, 
citrate, acetate
Decreased absorption T4 Adsorption or impaired gastric acidity
Proton pump 
inhibitor
Conflicting data Impaired gastric acidity
Raloxifene Decreased absorption T4 No in vitro study available
Ciproxin Decreased absorption T4 Interfering with thyroid hormone transport
Sevelamer 
hydrochloride
Decreased absorption T4 No in vitro study available
Chromium pilonate Decreased absorption T4 No in vitro study available
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acids, also markedly reduces LT4 absorption. The optimal time interval 
between ingestion of LT4 and colesevelam has not been studied. 
Colestipol, another bile sequestrant, reduces LT4 absorption in rats (72) 
but not in humans (73).
Ferrous sulphate decreases LT4 absorption, resulting in an increase 
in serum TSH (74). In vitro spectrophotometric studies showed that 
insoluble Fe3+-T4 complexes are formed, probably resulting in a 
reduction in intestinal LT4 absorption. Extrapolating the results from 
other studies on drug interactions with iron supplements (75), the 
authors suggest to separate the intake of LT4 and ferrous sulphate by at 
least 2 hours.
Conflicting results have been reported for the effect of sucralfate (used 
in reflux disease and gastritis) on LT4 absorption. Reduced and delayed 
absorption of LT4 was found in one study, which disappeared when 
the medications were taken 8 hours apart (76). These findings could 
be explained by binding of T4 by sucralfate as found in earlier in vitro 
experiments (77). Other studies, however, do not confirm the reduced 
bioavailability of LT4 by sucralfate (78, 79).
LT4 absorption is decreased by aluminium hydroxide (80-82). In 
vitro experiments show incremental LT4 adsorption with increasing 
concentrations of aluminium hydroxide, suggesting intraluminal 
sequestration of T4 by aluminium hydroxide. LT4 absorption may also be 
affected by formation of Al3+-T4 complexes.
The bioavailability of LT4 is also reduced by calcium carbonate (83, 
84). In vitro studies showed significant adsorption of T4 to calcium 
carbonate. A later study also showed impaired LT4 absorption with 
calcium citrate and calcium acetate (85).
The above-mentioned medications like calcium carbonate, aluminium 
hydroxide and sucralfate also interfere with gastric pH and/or acid 
secretion. As the in vitro studies in Caco2 cells have shown, pH is 
important for T4 uptake by intestinal cells. Low gastric acidity may thus 
contribute to the reduced bioavailability of LT4 with concomitant use of 
these drugs.
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As described above, there are conflicting reports on the effects of proton 
pump inhibitors (PPI) on LT4 absorption (33, 35-39). As with the above-
mentioned medications, low gastric acidity induced by proton pump 
inhibitors may reduce LT4 absorption. Two retrospective studies and 2 
prospective observational studies in a small group of patients showed 
that the LT4 daily dose had to be increased by 20-37% to reach the 
same therapeutic effect after starting PPI treatment (33, 36, 39). In two 
other studies LT4 absorption was unaltered with the use op PPIs during 
1 week (37, 38). This may suggest that only chronic oral PPI therapy is 
associated with decreased LT4 absorption.
Raloxifene, a selective estrogen receptor modulator, causes T4 
malabsorption when administered together with LT4, but not when 
the drugs are taken several hours apart (86). The mechanism for this 
reduced T4 absorption is unknown. Raloxifene is not known to adsorb or 
form complexes with other medications. The possibility of interference 
with a thyroid hormone transporter should be considered.
A more recent paper showed a blunted rise in serum T4 after ingestion 
of 1 mg LT4 together with the phosphate-binding drug sevelamer or the 
nutritional supplement chromium picolinate (87). The authors suggested 
that adsorption of LT4 to sevelamer or chromium, or alterations in 
mucosal transport processes may be the cause of the decreased T4 
absorption. In vitro experiments have not been performed to investigate 
these possible mechanisms.
Recently, reduced absorption of LT4 by the antibiotic ciprofloxacin has 
been described (88) which cannot be explained by binding of T4 to 
ciprofloxacin or reduced gastric acidity. The interaction by ciprofloxacin 
with a thyroid hormone transporter in the intestinal wall could offer 
an alternative explanation. Goldberg et al. show that the reduced 
absorption of LT4 by ciprofloxacin is consistent with inhibition of 
intestinal T4 transporters, possibly members of the OATP family, in 
particular OATP1A2 (89). Our in vitro experiments with Caco2 cells, 
however, showed no decreased T4 uptake in the presence of the 
prototypic OATP ligand BSP. OATP1A2 was shown to be present in Caco2 
cells in a study on transport of another quinolone antibacterial agent 
levofloxacin (90).
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Most of the studies on T4 malabsorption by other medications were 
performed before the importance of T4 transporters was established. 
Additional studies clarifying the role of specific intestinal (and liver) 
transporters in LT4 absorption, will also result in a better understanding 
of the interaction of LT4 with other drugs.
TImING oF THyroxINe INGesTIoN
Because of all the above mentioned factors possibly interfering with 
LT4 absorption, the moment of LT4 ingestion is important to maintain 
optimal and stable absorption. Patients are generally advised to take 
LT4 on an empty stomach. In 1977 Wenzel et al first reported on the 
influence of food on the absorption of LT4, and showed that absorption 
was significantly better in a fasting state than with simultaneous food 
intake. (52) The study of delayed T4 absorption with simultaneous food 
intake by Benvenga et al. (53) led to the current recommendations to 
ingest oral LT4 60 min prior to breakfast. In daily practice this stringent 
recommendation could potentially affect compliance. Furthermore, 
there are circadian differences in gastrointestinal function that could 
improve LT4 absorption when taken at night. Basal gastric acid secretion 
is highest in the late evening and lowest in the morning (91) and, 
as mentioned above, a low intestinal pH improves T4 absorption. In 
addition, bowel motility decreases at night (92), resulting in a more 
prolonged exposure of the intestinal wall to T4, which could further 
improve LT4 absorption. In the last couple of years a number of 
randomized trials have studied various timing options for LT4 intake and 
their effect on thyroid hormone parameters, variability of TSH values 
and quality of life (QOL). Bach-Huynh et al. showed that T4 is best 
absorbed when taken on an empty stomach, with at least 60 minutes 
separating LT4 and food intake (93). In a three-period crossover design 
they compared LT4 intake 1) 1 hour before breakfast, 2) with breakfast 
or 3) at bedtime at least 2 hours after the last meal of the day. TSH 
concentrations were higher when LT4 was taken at bedtime (TSH 2.19 
± 2.66 mU/l) and with breakfast (TSH 2.93 ± 3.29 mIU/l), compared 
with ingestion 60 min before breakfast (1.06 ± 1.23 mU/l). The non-
fasting regimens were also associated with more variable serum TSH 
concentrations. No changes in FT4 and T3 concentrations were seen. 
As the authors point out, only 19% of the eligible patients agreed to 
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participate, which may have resulted in a selection of patients who 
were rigorous in adhering to their medication, making the results less 
generalisable. In every day life, most patients find it difficult to postpone 
breakfast for 60 minutes after LT4 ingestion.
In a pilot study, later confirmed by a randomized double-blind crossover 
trial, we showed that LT4 taken at bedtime resulted in better thyroid 
hormone parameters, than when taken 30 min before breakfast (94, 
95). The pilot study also showed that the circadian pattern of TSH 
secretion remained intact with bedtime ingestion. This was an important 
finding, regarding the time of blood sampling for the analysis of the 
TSH levels. In the randomized trial, patients (n=90) were instructed to 
take 1 capsule in the morning and 1 capsule at bedtime (one containing 
LT4 and one containing placebo), with a switch after 3 months. Results 
showed that when LT4 was taken at bedtime, serum TSH levels 
decreased 1.25 mIU/l and FT4 and T3 levels increased compared to 
the morning intake. The higher TSH level with the morning LT4 intake 
suggests that an interval of 30 min between LT4 ingestion and taking 
breakfast may be too short to prevent interference with gastrointestinal 
absorption of LT4.
Finally, a recent randomized, open-label crossover study compared 
LT4 intake at least 60 minutes before breakfast with LT4 intake during 
breakfast (96). TSH level was higher when LT4 was taken with breakfast 
than on an empty stomach (TSH 2.89 vs 1.90 mIU/l). Intake with 
breakfast also resulted in more variability in TSH levels, which confirm 
the results of Bach-Huynh et al. (93).
In conclusion, all studies of the timing of LT4 intake conclude that 
absorption is maximal and most stable when the drug is taken on an 
empty stomach, with at least 60 minutes between tablet ingestion and 
food intake. LT4 intake at bedtime is a good alternative to morning 
intake, provided that LT4 is taken on an empty stomach. This regimen 
might be more convenient for patients that cannot postpone breakfast 
for 60 minutes in the morning.
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PseuDo-mAlABsorPTIoN
A relatively common problem in endocrine practice is persistent 
elevation of TSH in patients treated for hypothyroidism (97). The 
average replacement dose of LT4 varies from patient to patient, but 
is usually between 1.6-1.8 µg/kg. If much higher doses are required 
without adequate normalization of the thyroid hormone parameters, 
one should question the cause of this treatment failure. Rare causes 
like thyroid hormone resistance, or a TSH secreting pituitary adenoma 
show high TSH in combination with elevated FT4 levels. However, when 
despite high doses of LT4 raised TSH levels are seen with low FT4 
levels, malabsorption or pseudo-malabsorption (non-compliance) are 
the most common causes. First, compliance should be checked with the 
patient. LT4 should be taken on an empty stomach and intake of food 
should ideally be avoided for 60 minutes. Furthermore, drugs known to 
interfere with LT4 absorption/pharmacokinetics (Table 1 + 2) should be 
ingested with the appropriate time between LT4 and the drug(s). When 
these instructions do not improve thyroid hormone levels, all causes of 
LT4 malabsorption should be excluded (Table 2).
If all malabsorptive disorders are excluded, pseudo-malabsorption is 
the most probable cause. To prove this, a LT4 absorption test can be 
performed in a clinical setting. A single high dose of LT4 1000-2000 
Table 2 Factors interfering with LT4 treatment
Gastrointestinal disorders
Coeliac disease, H pylori gastritis atrophic 
gastritis, lactose intolerance, infections 
(giardia lambia)
Previous gastrointestinal surgery Jejuno(ileal) bypass, short bowel
Liver disease Cirrhosis, obstructive liver disease
Pancreatic disease Pancreatic insufficiency
Interfering medication- malabsorption Table 1
Interfering medication- change 
pharmacokinetics
Carbamazepine, phenytoin, phenobarbital, 
rifampicin, amiodarone, estrogen therapy
Dietary interference Interval between LT4 and food intake 
(minimum 60 min), fibre-enriched diet, soy 
products, coffee
Pregnancy Increases need LT4
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µg should be ingested by the patient under supervision of a nurse, to 
check proper ingestion and prevent surreptitious regurgitation (98, 99). 
TSH and FT4 levels should then be monitored over time (0, 2, 4 and 6 
hours after ingestion). No well-established standard is available to which 
individual patient results can be compared. However, from previous 
case reports and data on pharmacokinetics of LT4, it is known that peak 
absorption takes place 2-4 hours (5) after ingestion and FT4 levels 
should rise 50-100% above basal level (98, 99). Normalization of FT4 
levels also proves the absence of a malabsorptive disorder (100).
coNclusIoN
A stable and optimal absorption of LT4 is important in the treatment of 
patients with hypothyroidism. As described, absorption can be decreased 
by gastrointestinal disorders, including malabsorptive disorders and 
disorders impairing gastric acidity. From in vitro experiments in Caco2 
cells, the importance of a low pH for T4 uptake by intestinal transporters 
became apparent. Several, often commonly prescribed, drugs decrease 
the absorption of T4. This happens either by adsorption of LT4 to the 
interfering drug, by impaired gastric acidity, or by competition with a 
still unknown thyroid hormone transporter in the intestinal cell.
To ensure optimal absorption of LT4, patients are advised to take LT4 
on an empty stomach, with at least 60 minutes between LT4 and food 
ingestion. Bedtime LT4 intake is a more convenient alternative to 
morning intake, provided that LT4 is taken on an empty stomach. When 
patients have persistent elevation of TSH levels, despite high doses of 
LT4, malabsorption by gastrointestinal disorders or drugs should be 
excluded. When excluded, pseudo-malabsorption (non-compliance) is 
the most common cause, and a supervised high-dose LT4 absorption 
test can be performed.
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INTroDucTIoN
The prevalence of primary hypothyroidism keeps increasing, with iodine 
deficiency being the most common cause worldwide, and autoimmune 
thyroiditis being the most prevalent cause of hypothyroidism in 
developed countries with sufficient iodine intake. Treatment with 
synthetic T4 is available and seems to be the best substitute for the 
normal thyroid function. It has become increasingly clear, however, 
that treated hypothyroid patients regularly have remaining complaints. 
Nowadays, patients are becoming more assertive, assemble in patient 
platforms and demand an explanation for their reduced quality of life 
(QOL). Often they gather information on hypothyroidism on the internet 
and suggest possible alternative treatments. A better understanding of 
thyroid hormone (TH) absorption in the intestine and the reasons for the 
reduced QOL would help in the treatment of hypothyroid patients.
The problem in hypothyroidism is the decreased levels of serum T4 and 
T3, which cause a generalized slowing of metabolic processes in the 
human body. This results in complaints of cold intolerance, constipation, 
weight gain and hair loss. Also atherosclerosis, hypertension, 
dyslipidemia and depression can occur (1, 2). It is therefore important 
in the treatment of hypothyroidism to substitute the lack of TH in a 
way that mimicks the normal thyroid function as much as possible. 
Several studies on the best substitution therapy for hypothyroidism have 
shown that TH levels and complaints improve best by the treatment 
with synthetic T4, levothyroxine (LT4) (3). Therefore, international 
guidelines (4, 5) prescribe LT4, as the treatment of choice for patients 
with hypothyroidism. As several factors (food, drugs etc) can decrease 
LT4 uptake (6), instructions are that the patient should take LT4 in the 
morning on an empty stomach 30-60 minutes before breakfast. These 
strict instructions are not only inconvenient, frequently patients also 
have remaining complaints, even if TH levels have normalized.
In this thesis we 1) present bedtime LT4 intake as a good and more 
convenient alternative to morning intake, 2) describe the circadian rhythm 
of TSH, FT4 and T3 with morning and bedtime LT4 intake, 3) investigate 
the cause of reduced quality of life (QOL) in treated hypothyroid patients, 
4) characterize TH transport in a intestinal cell model and 5) describe the 
factors influencing LT4 uptake by the intestine.
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lT4 INTAke IN THe morNING
Shortly after the introduction of commercially available synthetic LT4 
in 1970, several studies appeared on the interference of intestinal 
diseases, and simultaneous intake of food and specific drugs with 
LT4 uptake (6). The package leaflet therefore states that LT4 should 
be taken on an empty stomach in the morning. Dutch prescibing 
information states that LT4 should be taken 30 minutes before 
breakfast, and American prescribing information advises an interval 
of 60 minutes before taking any food. Furthermore, other interfering 
drugs should be taken 2-6 hours after LT4 ingestion. For patients these 
instructions can be inconvenient because of their (work) schedule, 
concurrent illnesses (e.g. diabetes) and other drugs that should be 
taken before or with meals. This made us wonder if LT4 could be taken 
at another time of day, when the stomach is empty, for example at 
bedtime. When several patients in our outpatient clinic where positive 
about switching to bedtime LT4 intake, with improvement of their 
thyroid hormones, we decided to study the timing of LT4 intake in a 
randomized trial. We were interested in the effect on TH levels, but also 
in the possible changes in vital parameters (heart rate, body weight, 
blood pressure) and the effect on QOL.
lT4 INTAke AT BeDTIme
The first study we performed on bedtime LT4 intake in 11 patients 
(chapter 2) already showed a significant improvement in TH levels 
compared to morning LT4 intake (7). As this was not a blinded study, a 
better compliance with bedtime intake could have influenced the results. 
Therefore, it was necessary to perform a larger, randomized double-blind 
trial, to confirm the results of the pilot study. The cross-over design with 
capsules prepared by our hospital pharmacy (placebo and LT4), made 
it possible to study the effect of switching from morning to bedtime LT4 
intake (or vice versa) with patients (n=90) being their own controls.
The results described in chapter 3 showed that TSH levels decreased, 
and T4 and T3 levels increased with bedtime LT4 intake compared to 
morning LT4 intake (8). A possible explanation could be that basal 
gastric acid secretion is highest in the late evening and lowest in 
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the morning (9). In addition, bowel motility decreases at night (10), 
resulting in a more prolonged exposure of the intestinal wall to T4, 
which could further improve LT4 absorption. Also, the observation that 
serum FT4 increased after LT4 intake in the morning, but not with the 
bedtime intake in the pilot study, could point to the fact that there is a 
slower release of T4 with bedtime intake.
Five other studies examined the effect of different timing of LT4, 
especially in relation to food intake (11-15). A case study in 1995 in 
four patients showed that consuming breakfast within 20 minutes after 
LT4 intake resulted in higher TSH levels than when the same patients 
had breakfast 60 minutes after taking their LT4 (11). This small study 
led to the current recommendations in prescribing information to 
take LT4 60 minutes before breakfast. A retrospective study in elderly 
patients comparing LT4 intake at 9 a.m. with midnight intake (both 
postprandial) showed no difference in TSH levels (13). A parallel design 
study in newly diagnosed hypothyroid patients (with a mean TSH of 
80 mIU/l at the start of the study) showed no significant difference in 
TSH level with evening dosing compared to morning dosing after 12 
weeks of LT4 treatment. (14). Probably a steady state had not yet been 
reached in this trial. Only two other studies had a cross-over design like 
our study. An American trial, published around the same time as our 
study, compared 3 different times of LT4 intake (at least 1 hour before 
breakfast, with breakfast or at bedtime) for 8 weeks (15). The mean 
TSH levels seen with these different regimens were 1.06, 2.93 and 2.19 
mIU/l respectively. LT4 intake on an empty stomach in the morning, 
therefore, showed a lower TSH level than bedtime intake in this study, 
probably due to the longer time between breakfast and LT4 intake (60 
min versus 30 minutes in our study). A third cross-over study compared 
LT4 intake in the morning before or with breakfast, and showed more 
stable TSH values with intake on an empty stomach (12). Thus only 
2 studies comparing morning and evening LT4 intake (including ours) 
had a randomized controlled cross-over design. The main conclusion is 
that LT4 has to be taken on an empty stomach, with as much time as 
possible between LT4 intake and the ingestion of food or other drugs. If 
a patient has an empty stomach at bedtime, LT4 intake at that moment 
could be a good and perhaps more convenient alternative to morning 
intake.
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The performed studies influenced the guidelines on treatment 
of hypothyroidism. The Dutch guideline on thyroid disorders 
(Schildklierfunctiestoornissen 2012) states that bedtime LT4 intake is 
an alternative for morning intake. Two guidelines on hypothyroidism 
published by the American Thyroid Association (ATA) (4, 16), both 
mention our randomized trial and comment on the best time to take 
LT4. In the most recent guideline of December 2014 focusing on the 
treatment of hypothyroidism (4), the ATA incorporated a separate 
paragraph ‘Timing of levothyroxine administration’ describing the six 
studies discussed above. The authors summarize that the conditions 
associated with better absorption (ordered from best to most impaired) 
are 60 min before breakfast, bedtime, 30 minutes before breakfast, and 
with breakfast. Bedtime intake is therefore considered superior to intake 
30 minutes before breakfast, as Dutch pharmacies currently advise. 
The ATA also stresses that it is important to consider not only when LT4 
absorption is optimal, but also to be aware of what timing promotes 
adherence. If it is more convenient for a patient to take LT4. at bedtime, 
this will improve compliance and wil result in better and more stable TH 
levels.
cIrcADIAN rHyTHm oF TsH
In healthy subjects, thyrotropin (TSH) released by the pituitary gland, 
exhibits a circadian rhythm. Serum TSH levels increase in the evening, 
reach a maximum in the early night and decrease during the night (17, 
18). In addition to this nycthemeral pattern, repeated variably sized 
bursts of TSH release occur during the 24-hour period. TSH secretion 
is, therefore, partially pulsatile and partially basal. During the nocturnal 
TSH rise the burst frequency and amplitude increase. How TSH pulses 
are generated is not known, in contrast to the secretory pattern of other 
pituitary hormones (ACTH, GH, LH). What is known is that TSH secretion 
is under stimulatory control of thyrotropin releasing hormone (TRH) 
and the hormone leptin, gets negative feedback by T4 and T3 and is 
inhibited by the neurotransmitters somatostatin and dopamine (19). The 
circadian TSH rhythm is still present in mild hypothyroidism, disappears 
in overt hypothyroidism, but is restored with LT4 substitution (20). 
chapter 2 describes the 24 hour patterns of serum TSH, (F)T4 and T3 
with morning and bedtime LT4 intake in 11 hypothyroid patients (7). 
139General discussion
We confirmed the presence of a circadian TSH rhythm and showed that 
the pattern does not change when switching the time of LT4 ingestion 
to bedtime. Blood sampling in patients taking LT4 at bedtime can, 
therefore, still take place in the morning, as is usually done, without 
causing a systematic error in interpreting the results.
As was shown in previous studies (21), we demonstrated a transient 
peak in serum T4 and FT4 levels about 4 hours after morning LT4 
administration. This peak was not seen, however, with bedtime LT4 
intake, possibly explained by the reduced bowel motility at night (10), 
causing a slower release of T4 into the blood.
Our study showed a circadian pattern for FT4 and T4 both with morning 
and bedtime LT4. This pattern did change with bedtime LT4, showing a 
slightly decreased relative amplitude and a phase-advanced timing of 
their acrophase (earlier peak). Previous studies have shown conflicting 
data on diurnal rhythms in T4 and T3 (22, 23). Some publications 
suggest a relation between TSH and thyroid hormone secretion 
(23-25), but others do not (26), which may be explained by different 
experimental conditions and analytic tools. Changes in TH levels (total 
T4 and T3) could be explained by changes in serum protein levels 
effected by postural changes, but this does not explain the circadian 
pattern in FT4. The mechanism by which the circadian pattern of FT4 
and T4 is influenced by bedtime LT4 administration is therefore not 
easily explained.
Furthermore, the bioactivity of TSH also shows a circadian rhythm, with 
less bioactive and differently glycosylated TSH at night (27). So, while 
TSH levels are higher at night, the bioactivity of the hormone is less. We 
did not study the influence of different LT4 administration times on the 
bioactivity of TSH.
In recent years the sensitivity and precision of TSH assays have 
improved. Also the mathematical tools to interpret the 24-hour TSH 
pattern are much better, with the use of deconvolution methods 
(to quantify significant pulses, half-lives and basal secretion) and 
approximate entropy (quantifying the pattern orderliness) (19). This 
has provided information about the influence of age, gender, BMI and 
sleep on the circadian TSH pattern. With these modern methods more 
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information could be gathered in future studies about the change in 
TSH pulse frequency, pulse shape and half-lives when changing the 
administration time of LT4. Studying the circadian patterns of TSH and 
thyroid hormones with different treatments of hypothyroidism (LT4, 
T3/T4 combination) could help to find the best way to mimick normal 
thyroid function.
quAlITy oF lIFe IN HyPoTHyroIDIsm
Despite improved thyroid parameters with bedtime LT4, QOL did 
not improve in these patients. In general, in newly diagnosed 
hypothyroidism, symptoms and signs improve quickly after starting LT4. 
However, when the treatment target is reached, with TH levels within 
the reference range, patients frequently have remaining complaints. 
Clinicians encounter this problem in hypothyroid patients on a daily 
basis.
To find an explanation for the reduced QOL, we performed a post-hoc 
analysis on the collected data from our randomized trial on bedtime LT4 
in hypothyroid patients, of which the results are described in chapter 4 
(28).
A reduced QOL in these patients was confirmed when comparing the 
QOL scores with a healthy population. No relation was found between 
QOL and thyroid parameters, as other studies had already shown (29, 
30). The parameter that did have a relation with QOL was BMI, with a 
higher BMI leading to a worse QOL. BMI in our population was indeed 
markedly higher than the BMI in the general Dutch population. The 
weight gain observed in patients with hypothyroidism is a result of 
the decreased metabolism. When treatment is started, however, most 
patients struggle to loose the gained weight, and often do not succeed. 
It is known that QOL is reduced in overweight people in general (31), 
and in hypothyroid people it seems to explain a large part of the reduced 
QOL. Therefore, the prevention of weight gain requires attention in the 
treatment of hypothyroid patients and in future studies.
Possible improvements could be aimed at diagnosing hypothyroidism at 
an earlier stage (for example with a screening program in a high risk 
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population), or adaptations in the treatment of hypothyroidism. A more 
rapid normalization of TH levels with a full starting dose of LT4 (1.6 µg/
kg) would seem beneficial, but a randomized trial showed no change in 
QOL scores or body weight compared to a low starting dose (32). Aiming 
at a lower target TSH was also studied, but did not give an improvement 
of QOL scores (33). Also, TSH levels below the lower reference range are 
not recommended, because this increases the risk of atrial fibrillation 
(34) and osteoporosis (35). Studies on treatment with desiccated TH 
(36) or T4/T3 combination therapy (3, 37) showed no improvement in 
QOL compared to LT4 monotherapy. However, two studies did show a 
patient preference for T4/T3 combination therapy (37) or dessicated 
TH (36), a result possibly explained by its association with weight loss. 
Other studies have shown that LT3 monotherapy is associated with 
decreased body weight and improved lipid levels (38). This treatment, 
however, results in an unwanted reduction in TSH and FT4 levels.
Of course, not all patients with a reduced QOL are overweight, and 
BMI does not explain complaints in all hypothyroid patients. Recent 
studies (39) have linked reduced QOL in some hypothyroid patients to 
a type 2 deiodase polymorphism, DIO2-Thr92Ala, causing a reduced 
peripheral conversion of T4 into the active T3. In these specific patients, 
combination T4/T3 therapy is thought to be beneficial. In vitro studies, 
however, have failed until now to show a consistent functional effect 
of this DIO2 polymorphism(40). Further research needs to give more 
insight in this hypothesis.
As was discussed earlier, also T4 and T3 vary during the day, with the 
stimuli and inhibitory factors largely unknown. The current treatment 
with exogenous T4 does not reproduce endogenous serum T4 excursions 
or serum T3 rhythms. This could also explain the fact that T4/T3 
combination therapy has not resulted in improved well being, as T3 
taken once or twice daily may not replicate the physiologic nature of T3 
secretion. Perhaps the development of a sustained release preparation 
could mimick the normal diurnal rhythm of T4 and T3 in the future.
An additional problem is that serum TH levels might not represent 
TH levels in different tissues, because of varying expression and 
function of TH transporters and deiodinases. A good marker of tissue 
TH status would, therefore, be helpful. Tissue biomarkers of thyroid 
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hormone include sex hormone binding globulin (SHBG), osteocalcin, 
urinary n-telopeptides, total cholesterol, low-density lipoprotein (LDL) 
cholesterol, lipoprotein(a), creatine kinase, ferritin, myoglobin, and 
enzymes such as tissue plasminogen activator, angiotensin converting 
enzyme (ACE) and glucose-6-phospate dehydrogenase (4). The results 
of RCTs have shown that SHBG (30) and total cholesterol (30, 41) are 
particularly affected by the administration of LT4. These biomarkers, 
however, are not sensitive and specific, or standardized, as was also 
seen with SHBG in our randomized study on bedtime LT4. One study 
on LT4 substitution showed that resting energy expenditure was 
altered by change in LT4 dose and correlated well with TSH (42). The 
additional value to TSH levels in the clinical setting however is not 
clear. Measurement of TH responsive gene expression is a means of 
assessing the impact of TH on various tissues. TH effects on rodent and 
cell models have been extensively studied (43). Measurement of gene 
expression, however, cannot be routinely used to asses TH status, as it 
would require invasive procedures such as taking tissue biopsies.
In conclusion, at this moment LT4 remains the best treatment for 
patients with hypothyroidism, but hopefully treatment in the future can 
be more customized to the individual hypothyroid patient, taking the 
individual setpoint and TH metabolism into accoount. To accomplish this, 
large prospective parallel studies are probably needed to study different 
treatment modalities rather than short-term cross-over studies.
INTesTINAl cell moDel sTuDyING uPTAke T4 AND 
T3
As mentioned before, the active hormone T3 needs to be transported 
into the cell to stimulate the nuclear TRs. As endogenous T4 and T3 
lack in hypothyroidism, these hormones need to be substituted by oral 
administration. In the intestine, T4 has to be absorbed at the apical 
side of the enterocytes, transported through the cell, and released into 
the circulation at the basolateral side. TH transport in different tissues 
involves different transporters. In chapter 5 TH transport in intestinal 
cells is characterized using the colon carcinoma (Caco2) cell line as 
a model. This cell line in vitro undergoes spontaneous enterocytic 
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differentiation, and is therefore a frequently used model to study 
transport in the small intestine.
The results show that the uptake of T3 and T4 in enterocytes is 
regulated by different transporters. T4 uptake in the Caco2 cell is 
increased at a lower pH and inhibition studies with prototypic ligands for 
known TH transporters suggested that the L-type amino acid transporter 
LAT1 is involved in this T4 transport.
MCT10 seems to be important for T3 transport in Caco2 cells, because of 
the Na+ and pH independence, inhibition of T3 uptake by MCT10 ligands, 
and reduced T3 uptake after silencing MCT10 with siRNA.
These data are important in the understanding of T4 and T3 uptake 
by intestinal cells. The study marks only the beginning, however, of 
our knowledge about TH transport by the intestine. We do not know 
if TH transport in Caco2 cells represents TH uptake in vivo in the 
human intestine. Although LAT1 and MCT10 are present in the human 
enterocyte, the expression and localization in the cell will influence 
the uptake in vivo. LAT1 is present in the small intestine (44), but its 
localization at the apical or basolateral membrane of the eneterocyte is 
not clear. MCT10 is at the basolateral membrane of the enterocyte (45), 
and may be important for the transport of T3 through the cell, but will 
need a different transporter at the apical membrane for uptake from the 
lumen.
Future research is needed to fully understand intestinal TH transport. 
Currently, our lab studies TH transport in Caco2 cells in transwells 
to get more information on transcellular transport in polarized cells. 
Experiments can also be performed using intestinal cells isolated from 
mouse models, as has been done for studies of the intestinal transport 
of other substances (46). Unfortunately, it is not yet possible to culture 
a stable cell line of human enterocytes, as biopsies of the small intestine 
contain different cell types. To make sure that future studies on thyroid 
hormone transport are conducted well and results from different groups 
can be compared the ATA published a guideline on how to investigate 
thyroid hormone transport in a cell model (43).
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FAcTors INFlueNcING INTesTINAl T4 uPTAke
Treating patients with hypothyroidism is a challenge with all the factors 
influencing the absorption of T4. The studies described in this thesis 
provided valuable information on T4 uptake by the intestine. Chapter 
6 gives an overview of conditions of the intestinal tract, drugs and 
food decreasing the uptake of T4. Also the best timing of LT4 intake 
is discussed using the study results described in chapter 2 and 3. The 
importance of an acidic environment is stressed, with description of 
clinical conditions influencing the acidity of the stomach/ intestine. The 
data from the basal experiments in Caco2 cells are used to show the pH 
dependent transport of T4 in intestinal cells. New forms of T4 (capsules 
and oral liquid) are described that could be less dependent on pH and 
factors decreasing absorption by the intestine. In some patients TSH 
levels stay high despite high dose of LT4. Practical guidelines are given 
how to approach these patients. Factors decreasing LT4 absorption 
should be excluded, but if no reason for malabsorption can be found, 
pseudomalabsorption (noncompliance) should be considered. A guideline 
is given how to approach this problem.
coNclusIoN
In this thesis the treatment of hypothyroidism and absorption of T4 is 
described from a clinical and basic point of view. Put together the thesis 
gives insight in the factors influencing LT4 absorption and its results 
have influenced the timing of LT4 intake. The study of T4 uptake in 
Caco2 cells has given the first data on characteristics of intestinal T4 
and T3 uptake. With these data further research can be performed, 
which will hopefully unravel the (different) transporter(s) involved in TH 
transport in intestinal cells.
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153Summary
The normal thyroid gland produces the thyroid hormones, thyroxine 
(T4) and triiodothyronine (T3) under the influence of thyrotropin (TSH), 
produced by the pituitary gland. Thyroid hormone is essential for the 
regulation of energy metabolism in virtually all tissues. A lack of thyroid 
hormone, hypothyroidism, results in complaints of fatigue, weight 
gain, constipation and cold intolerance. Hypothyroidism is treated by 
replacing the lack of thyroid hormone by synthetic T4, levothyroxine. To 
guarantee the absorption of levothyroxine from the intestine, prescribing 
information advise intake of the tablet on an empty stomach, 30-60 
minutes before breakfast. These instructions can be inconvenient for 
patients, and might influence the compliance. Furthermore, the reason 
for the reduced quality of life (QOL) in many treated hypothyroid 
patients has not been cleared up. This thesis describes the treatment 
of hypothyroidism and the absorption of (synthetic) T4 in the intestinal 
tract.
chapter 1 provides the necessary background information on 
hypothyroidism and the treatment with levothyroxine. In the next 
chapters the performed studies are described
In the outpatient clinic we observed several patients that had an 
improvement in thyroid hormone levels and well being when they took 
levothyroxine at bedtime instead of in the morning. This prompted us to 
study the effect of switching levothyroxine intake from the morning to 
bedtime. As TSH has a circadian rhythm, we first studied the effect of 
bedtime levothyroxine on TSH and thyroid hormone profiles. chapter 2 
describes a study in 11 hypothyroid patients treated with levothyroxine. 
A significant difference in TSH, T4 and T3 was found after switching to 
bedtime administration of levothyroxine. The circadian rhythm of TSH 
stayed intact. chapter 3 describes a randomized, double blind crossover 
trial in 90 patients on levothyroxine intake in the morning versus at 
bedtime. This trial confirmed the improved thyroid hormone levels 
with bedtime levothyroxine intake. Levothyroxine intake at bedtime 
is therefore a good alternative to morning levothyroxine intake. QOL 
parameters showed no significant changes, however. As the reduced 
QOL in hypothyroid patients is not understood, we performed a post-hoc 
analysis on the relation of QOL and the various parameters measured in 
the randomized trial. chapter 4 shows an inverse relationship between 
QOL and BMI in our cohort. Weight gain thus needs more attention 
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in the treatment of hypothyroidism. A relationship between QOL and 
thyroid hormone levels could not be found.
To clarify the mechanism of thyroid hormone uptake in the small 
intestine, we studied the transport of T4 and T3 in an intestinal cell 
model, the human colorectal adenocarcinoma cell line (Caco2). After 
reaching confluence, Caco2 cells differentiate spontaneously into 
enterocyte-like cells, and are therefore commonly used to study 
transport of various compounds in the small intestine. In chapter 5 
the characteristics of T4 and T3 transport in Caco2 cells are described. 
Evidence is provided that amino acid transporters are important for 
uptake of T4 and T3 by Caco2 cells. T4 uptake is Na+ independent 
and pH dependent, and inhibition studies suggest that it is mediated 
by the L-type amino acid transporter, LAT1. T3 uptake is Na+ - and 
pH independent, and appears to be mediated by a T-type amino acid 
transporter, most likely MCT10. More experiments are required to 
identify the transporters responsible for thyoid hormone transport in the 
human intestine.
In the treatment of hypothyroid patients, an adequate absorption 
of levothyroxine by the intestine is essential. chapter 6 gives an 
overview of the available data on levothyroxine absorption and factors 
interfering with this absorption. Interference of levothyroxine uptake by 
gastrointestinal disorders, food and several drugs are described, and an 
advise is given on the best time of levothyroxine intake. When thyroid 
hormone levels do not return to normal, despite adequate levothyroxine 
treatment, malabsorption should be excluded.
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De schildklier ligt aan de voorzijde van de hals, voor het strottenhoofd, 
en maakt schildklierhormoon uit jodium en tyrosine. Zo ontstaat het 
inactieve hormoon thyroxine, T4. Als er een joodatoom van T4 wordt 
afgescheiden ontstaat het actieve hormoon, T3. De schildklier maakt 
met name T4 en ook een kleine hoeveelheid T3. Het grootste deel 
van het actieve T3 wordt omgezet vanuit T4 in de weefsels waar het 
op dat moment nodig is. De aanmaak van T4 wordt geregeld door 
de hypothalamus en de hypofyse in de hersenen. De hypothalamus 
stimuleert de hypofyse om schildklier stimulerend hormoon 
(thyroidstimulerend hormoon, TSH) af te scheiden, wat op zijn beurt de 
schildklier activeert om T4 te maken. Doordat T4 en T3 de hypothalamus 
en hypofyse weer remmen, wordt de hoeveelheid schildklierhormoon 
in het bloed binnen nauwe grenzen gehouden. Schildklierhormoon is 
belangrijk voor de stofwisseling in vrijwel alle weefsels in het lichaam. 
Een te traag werkende schildklier, hypothyreoidie, leidt tot een te 
trage stofwisseling. Hierbij ontstaan klachten zoals vermoeidheid, 
gewichtstoename, obstipatie en kouwelijkheid.
In de behandeling van hypothyreoïdie moet het tekort aan 
schildklierhormoon worden aangevuld op een manier die het meest de 
natuurlijke werking van schildklierhormoon nabootst. Vroeger werd 
hiervoor gedroogd dierlijk schildklierhormoon gebruikt. De hoeveelheid 
T4 en T3 was hierbij echter zeer variabel per medicijn. Sinds de 
70-er jaren is nagemaakt (synthetisch) T4, genaamd levothyroxine, 
beschikbaar als behandeling. Hiermee kan een constante hoeveelheid 
T4 worden ingenomen, die in het lichaam wordt omgezet in actief T3. 
De huidige internationale richtlijnen schrijven levothyroxine voor als 
behandeling voor mensen met hypothyreoïdie. Hiermee kunnen de 
schildklierhormoonwaarden in het bloed weer worden hersteld. Om 
goede opname van levothyroxine in de darm te garanderen moet de 
tablet op een nuchtere maag worden ingenomen, omdat anders de 
opname verminderd kan worden door voedsel of andere medicijnen. 
De bijsluiter vermeldt daarom dat de tablet minstens een half uur 
voor het ontbijt moet worden ingenomen. Het kan lastig zijn voor 
patiënten om te wachten met ontbijt, wat de therapietrouw negatief 
kan beïnvloeden. Daarnaast blijven sommige patiënten klachten houden 
van hypothyreoïdie ondanks dat de schildklierhormoonwaarden in het 
bloed adequaat zijn. Dit proefschrift beschrijft de behandeling van 
hypothyreoïdie en de opname van levothyroxine door de darm. In 
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Hoofdstuk 1 wordt achtergrondinformatie over hypothyreoidie en de 
behandeling gegeven en worden de verrichtte studies ingeleid. In de 
volgende hoofdstukken worden de studies beschreven.
Op de polikliniek Interne Geneeskunde zagen wij enkele patiënten 
die zich beter voelden als ze de tablet levothyroxine ’s avonds 
voor het slapengaan innamen, met hierbij ook verbeterde 
schildklierhormoon waarden. Dit was de reden om te onderzoeken 
of inname van levothyroxine rond bedtijd inderdaad een verbetering 
van schildklierwaarden geeft, en wat het effect op kwaliteit van leven 
is. Omdat TSH een dagritme heeft, met hogere waarden in de vroege 
nacht, werd eerst een studie verricht in een kleine groep patiënten 
om het effect van een ander inname tijdstip op het TSH dagritme te 
onderzoeken. Als het dagritme hierdoor verandert, moet hier namelijk 
rekening mee worden gehouden bij het tijdstip van bloedafname. In 
Hoofdstuk 2 wordt de studie beschreven waarbij in in 11 patiënten 
die levothyroxine gebruikten, gedurende 24 uur elk uur bloed werd 
afgenomen. Na deze dag werd de patiënten gevraagd om de tablet 
levothyroxine ’s avonds in te gaan nemen. Na 2 maanden werd opnieuw 
gedurende 24 uur bloed afgenomen. In deze kleine groep patiënten 
bleken de schildklierwaarden bij de avondinname al verbeterd, met 
een lager TSH en hogere T4 en T3 waarden. Het TSH dagritme bleef 
onveranderd met de avondinname van levothyroxine.
Om de resultaten van de kleine studie te bevestigen werd een grotere 
studie in 90 patiënten uitgevoerd die in Hoofdstuk 3 wordt beschreven. 
Gedurende 6 maanden slikten patienten met hypothyreoidie ’s ochtends 
en ’s avonds een capsule waarvan de een levothyroxine bevatte en de 
andere een placebo. Na 3 maanden werden de capsules omgewisseld 
(cross over). Via loting (randomisatie) bij de apotheek, werd bepaald 
of een patiënt eerst levothyroxine in de ochtend of in de avond slikte. 
Zowel de patiënt als de dokter waren niet op de hoogte welke capsule de 
werkzame stof bevatte (dubbelblind). Elke 6 weken werden de patiënten 
teruggezien op de polikliniek en werd bloed geprikt en werden gewicht, 
hartslag en bloeddruk gemeten. Aan het begin, halverwege en aan het 
einde van de studie vulden de mensen 3 vragenlijsten in die de kwaliteit 
van leven meetten. Na afloop van de studie bleek inderdaad het TSH 
gehalte lager en de T4 en T3 waarden hoger bij avondinname van 
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levothyroxine. Dit wordt mogelijk verklaard door betere opname door de 
darm in de avond.
Ondanks de verbeterde schildklierhormoon waarden, was er geen 
verbetering in de kwaliteit van leven. In Hoofdstuk 4 wordt de reden 
van de verminderde kwaliteit onderzocht door de verzamelde gegevens 
uit de gerandomiseerde studie te analyseren. Hierbij blijkt er geen 
relatie tussen schildklierhormoon waarden en kwaliteit van leven. 
Dit bevestigt de resultaten van eerdere studies. Wel bleek een hoger 
gewicht, en dus een hogere body mass index (BMI, kg/m2) gerelateerd 
aan een slechtere kwaliteit van leven. Gewichtstoename behoeft daarom 
extra aandacht in de behandeling van patiënten met hypothyreoïdie. In 
de discussie van het hoofdstuk wordt ook ingegaan op andere mogelijke 
redenen van een verminderde kwaliteit van leven. Onder andere is er 
een mogelijkheid dat de hoeveelheid schildklierhormon in het bloed niet 
de hoeveelheid schildklierhormoon in de perifere weefsels weergeeft. 
Er is echter geen goede methode beschikbaar om de hoeveelheid 
schildklierhormoon in de weefsels makkelijk te meten. Ook zou het 
kunnen dat sommige patiënten waarbij de omzetting van T4 naar T3 
minder goed verloopt, meer gebaat zijn bij een combinatie van T4 en 
T3 therapie. Meer onderzoek naar de beste individuele behandeling van 
hypothyreoïdie is noodzakelijk om de kwaliteit van leven van mensen 
met hypothyreoïdie te verbeteren.
Tijdens de studies naar avondinname van levothyroxine bleek dat het 
mechanisme van schildklier opname door de darm nog niet volledig 
was opgehelderd. Uit eerdere studies was wel gebleken dat de opname 
(transport) vooral plaats vindt in de twaalfvingerige darm en de dunne 
darm, echter hoe het schildklierhormoon de celwand passeert is niet 
duidelijk. In het laboratorium van de afdeling Interne Geneeskunde/ 
Endocrinologie van het Erasmus MC bleek het mogelijk om het transport 
van schildklierhormoon door de darmcel te bestuderen. De verrichtte 
experimenten worden beschreven in Hoofdstuk 5. Aangezien er 
geen menselijke dunne darmcellen beschikbaar zijn waarin transport 
kan worden bestudeerd, werden cellen van een dikke darm tumor 
(coloncarcinoom, Caco2) gebruikt die bij groei sterk lijken op de 
dunne darmcel. Om die reden wordt deze cellijn vaak gebruikt om 
transport in de dunne darm te bestuderen. Aanvankelijk werd gedacht 
dat schildklierhormoon de celwand gewoon kon passeren (diffusie). 
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Er is echter gebleken dat schildklierhormoon een transporter eiwit 
(soort celpoortje) nodig heeft om de celwand te passeren en de 
binnenkant van de cel te bereiken. Uit eerder onderzoek is gebleken dat 
schildklierhormoon transport in verschillende cel soorten in het lichaam 
gebeurt door verschillende transporter eiwitten. Deze verschillende 
transporters hebben allemaal karakteristieke eigenschappen die het 
transport van stoffen bevorderen of remmen. Om de karakteristieken 
van het schildklierhormoon transport in de darmcellen te achterhalen 
werden diverse experimenten uitgevoerd. Hieruit is gebleken dat 
transport van T4 en T3 waarschijnlijk gebeurt door verschillende 
transporters. Voor beide hormonen is het transport niet afhankelijk van 
een zout milieu (natrium). T4 transport is echter, in tegenstelling tot 
T3 transport, zeer afhankelijk van de zuurtegraad van de omgeving. Bij 
een zuur milieu (lage pH) is de opname van T4 veel beter. Vervolgens 
werden er bij de opname experimenten diverse stoffen toegevoegd 
waarvan bekend is dat zij bekende transporters kunnen blokkeren. 
Als de opname van T4 of T3 geremd wordt bij het toevoegen van een 
bepaalde stof, kan dit een sterke aanwijzing zijn dat de betreffende 
transporter betrokken is bij het schildklierhormoon transport. Hieruit 
kwam naar voren dat de transporter LAT1 een belangrijke rol lijkt te 
spelen bij de opname van T4 in de Caco2 cel. Voor de opname van T3 
lijkt de transporter MCT10 van belang. De vraag blijft in hoeverre de 
opname van T4 en T3 in het cel model Caco2 een afspiegeling is van 
de werkelijke opname in de darmcel van de mens. Het is bekend dat de 
genoemde transporters aanwezig zijn in de dunne darmcel bij de mens. 
Het eiwit MCT10 lijkt zich echter aan de onderkant (basolaterale zijde) 
van de cel te bevinden, zodat het niet direct betrokken kan zijn bij de 
opname van T3. Mogelijk beïnvloedt MCT10 de uitwisseling van stoffen 
door een andere tranporter die zich wel aan de darmzijde (apicale 
zijde) van de cel bevindt. Waar de transporter LAT1 zich precies in de 
menselijke darmcel bevindt is nog niet duidelijk. Aanvullend onderzoek 
lijkt dus noodzakelijk om de exacte manier van schildklierhormoon 
opname door de darm op te helderen. In ieder geval hebben de 
verrichtte experimenten al veel meer inzicht gegeven over de mogelijke 
kandidaat transporters voor schildklierhormoon.
In Hoofdstuk 6 wordt een overzicht gegeven van alle factoren die 
de opname van levothyroxine in de darm kunnen beïnvloeden. De 
verschillende darmaandoeningen, zoals glutenintolerantie (coeliakie), 
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maagontsteking (gastritis) en darmoperaties, die de opname van 
levothyroxine kunnen verminderen worden beschreven. Ook worden 
alle medicijnen en voedingsstoffen die de opname van levothyroxine 
beïnvloeden beschreven. Een advies wordt gegeven over het beste 
tijdstip om levothyroxine in te nemen. Ten slotte, worden adviezen 
gegeven voor het probleem waarbij het TSH gehalte hoog blijft, ondanks 
een hoge dosis levothyroxine. Als alle factoren die levothyroxine negatief 
beinvloeden zijn uitgesloten, duidt dit meestal op therapieontrouw.
Ten slotte wordt in Hoofdstuk 7 een overzicht gegeven van de verrichtte 
studies, en wordt besproken wat de invloed van de studies is op de 
dagelijkse praktijk. Verder worden suggesties gedaan voor verder 
onderzoek in de toekomst.
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